VILNIUS UNIVERSITY
FACULTY OF MEDICINE

Medicine

Institute of Clinical Medicine, Clinic of Anesthesiology and Intensive Care

Abhishek Krishna Sharma, 6th year, group 9

INTEGRATED STUDY MASTER'S THESIS

Beyond the Label: a Literature Review on the Neurotoxic Effects of Everyday Medications

Supervisor: Prof. Dr. Robertas Badaras

Head of the department or clinic: Prof. Dr. (HP) Jūratė Šipylaitė

Vilnius, 2025

Student's email: abhishek.sharma@mf.stud.vu.lt

Table of Contents

1. List of Abbreviations

Abbreviation	Definition
AChE	Acetylcholinesterase
ADR	Adverse Drug Reaction
AEDs	Antiepileptic Drugs
ALL	Acute Lymphoblastic Leukemia
AMPA	α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ATP	Adenosine Triphosphate
BBB	Blood-Brain Barrier
CKD	Chronic Kidney Disease
CICI	Chemotherapy-Induced Cognitive Impairment
CIPN	Chemotherapy-Induced Peripheral Neuropathy
CNS	Central Nervous System
COX-2	Cyclooxygenase-2
CYP2C19	Cytochrome P450 Family 2 Subfamily C Member 19
CYP2D6	Cytochrome P450 Family 2 Subfamily D Member 6
CYP450	Cytochrome P450 Enzyme System
DNA	Deoxyribonucleic Acid
DXR	Doxorubicin
GABA	Gamma-Aminobutyric Acid
GERD	Gastroesophageal Reflux Disease
HLA allele	Human Leukocyte Antigen
HMGCR	HMG-CoA Reductase
LDL	Low-Density Lipoprotein
LPS	Lipopolysaccharide
LTP	Long-Term Potentiation
MDA	Malondialdehyde
MMSE	Mini-Mental State Examination
MRI	Magnetic Resonance Imaging
MTX	Methotrexate
NAM	Necrotizing Autoimmune Myopathy
NF-κB	Nuclear Factor Kappa B
NSAID	Nonsteroidal Anti-Inflammatory Drug
NSAHs	Non-Sedating Antihistamines
OP	Organophosphate
PPI	Proton Pump Inhibitor
PV	Polycythaemia Vera
ROS	Reactive Oxygen Species
SAMS	Statin-Associated Muscle Symptoms
SOD	Superoxide Dismutase
SSRI	Selective Serotonin Reuptake Inhibitor
TNBC	Triple-Negative Breast Cancer
TNF-α	Tumour Necrosis Factor Alpha

2. Abstract

Medications are fundamental to modern healthcare, significantly improving patient outcomes across a wide range of conditions. However, increasing evidence shows that many commonly prescribed drugs can have unintended neurotoxic effects, potentially impacting cognition, emotions and the integrity of our nervous systems. Despite their therapeutic benefits, these adverse effects are often underrecognized or misattributed, particularly in older adults or patients with complex comorbidities. The aim of this literature review is to evaluate the neurotoxic potential of commonly prescribed medications and raise physician awareness to promote safer prescribing practices. A systematic review of the literature was conducted using databases such as PubMed, ScienceDirect, and Google Scholar, with a focus on peer-reviewed articles published in the last two decades. Included sources ranged from clinical trials and observational cohort studies to case reports and mechanistic research involving in vitro and animal models. Neurotoxicity was assessed based on mechanisms such as oxidative stress, mitochondrial dysfunction, neurotransmitter imbalances, excitotoxicity, neuroinflammation, ion channel disruption, and alterations to the blood-brain barrier. Additional risk factors considered included polypharmacy, age, genetic polymorphisms (e.g., Cytochrome variants, alleles), comorbid conditions, and nutrient deficiencies. The results highlight that cardiovascular drugs such as statins and beta-blockers are associated with memory loss, mood changes, and in some cases, suspected links to neurodegenerative conditions. Proton pump inhibitors are linked to memory impairment through pathways involving vitamin B12 deficiency and gut microbiome disruption. Psychiatric medications, including selective serotonin reuptake inhibitors and benzodiazepines, are implicated in serotonin syndrome, long-term dependence, and impaired cognition. Antiepileptic drugs have been found to contribute to sedation, cognitive slowing, and developmental risks in certain populations. Fluoroquinolone antibiotics are associated with mitochondrial toxicity, peripheral neuropathy, and seizures. Chemotherapy agents, particularly platinum compounds and taxanes, are strongly linked to chemotherapy-induced peripheral neuropathy and cognitive impairment, commonly referred to as “chemo brain.” In conclusion, neurotoxicity from widely used medications presents a significant clinical concern. Greater emphasis should be placed on early detection, patient-specific risk stratification, and integration of pharmacogenomic data to reduce neurotoxic risks. Personalized prescribing, combined with better education on neurotoxic side effects, can help minimize harm. Further research is essential to clarify the underlying mechanisms, identify at-risk populations, and develop neuroprotective strategies to support long-term neurological health in patients requiring chronic pharmacotherapy.

3. Introduction

The human body's intricate systems are both a marvel and a complex interplay of delicate processes, with the nervous system serving as a pivotal yet vulnerable network. Medications, integral to modern healthcare, play a crucial role in managing diseases and alleviating symptoms. However, their unintended effects, particularly on the nervous system, present a multifaceted challenge that warrants deeper understanding. Among these challenges is the largely underexplored area of neurotoxicity induced by commonly prescribed medications – a phenomenon that can manifest in subtle or profound ways, affecting both short-term and long-term patient well-being. How do medications that are essential for treating chronic conditions or life-threatening illnesses lead to adverse neurological outcomes? What mechanisms govern these effects, and how can they be mitigated to ensure safer therapeutic practices? These questions form the foundation of this paper, which aims to examine the neurotoxic effects of commonly prescribed medications, elucidating their clinical implications and providing practical insights for healthcare professionals.

The relevance of this topic is underlined by the increasing reliance on pharmacotherapy, particularly among aging populations and individuals subjected to polypharmacy. With the nervous system being highly sensitive to disruptions in biochemical and cellular processes, the potential for neurotoxicity from medications is of considerable concern. This paper addresses the need for a comprehensive review of the mechanistic underpinnings, clinical manifestations, and risk factors associated with drug-induced neurotoxicity across a spectrum of drug classes. By exploring medications ranging from cardiovascular agents like statins and beta-blockers to psychiatric drugs such as Selective Serotonin Reuptake Inhibitors (SSRIs) and antiepileptic drugs (AEDs), as well as chemotherapy agents and gastrointestinal medications like Proton Pump Inhibitors (PPIs) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), this review provides a nuanced understanding of their impacts on neurological health.

The systematic literature review methodology ensures a rigorous approach to synthesizing existing research. By critically analyzing findings from clinical trials, observational studies, and mechanistic research, this paper identifies patterns across drug classes and highlights the interplay of factors such as oxidative stress, mitochondrial dysfunction, neurotransmitter dysregulation, and inflammation in mediating neurotoxicity. Emerging modalities like metabolomics and proteomics offer further dimensions to the exploration of drug effects and are discussed for their potential in advancing this field.

Despite significant advances in understanding the neurotoxic effects of certain drug classes, such as chemotherapy agents, gaps remain in the literature concerning others, including gastrointestinal drugs and antihistamines. These gaps are compounded by the variability of neurotoxic outcomes based on individual patient characteristics, such as genetic predispositions, comorbidities, and polypharmacy. This paper emphasizes the importance of integrating clinical observations and mechanistic evidence to address these limitations, with the ultimate goal of informing safer prescribing practices.

The aim of this work is to evaluate the neurotoxic effects of commonly prescribed drugs and their impact on clinical practice. The objectives of this literature review are to: Identify drug classes commonly associated with neurotoxicity; establish the underlying mechanisms underlying these effects; highlight clinical manifestations and risk factors; and discuss safer drug prescribing practices. The significance of this work is to increase awareness among healthcare professionals and improve patient outcomes by integrating mechanistic insights with clinical observations.

The structure of this paper is designed to provide a logical progression through the topic. Following this introductory chapter, Chapter 4 defines and classifies neurotoxicity, exploring its underlying mechanisms and risk factors. Chapter 5 investigates cardiovascular medications, focusing on statins and beta-blockers, while Chapter 6 discusses gastrointestinal and anti-inflammatory drugs such as PPIs, NSAIDs, and antihistamines. Chapter 7 examines psychiatric and neurological drugs, including SSRIs and AEDs. Chapter 8 explores the neurotoxicity of fluoroquinolones, before Chapter 9 delves into the neurotoxic effects of cancer treatments, particularly chemotherapy agents. The concluding chapter synthesizes the findings and offers recommendations for healthcare professionals.

4. Methodology

This thesis employed a narrative literature review approach to explore the neurotoxic effects associated with commonly used medications. The primary aim was to synthesize available knowledge across a diverse range of drug classes, with a focus on identifying both direct and indirect neurotoxic mechanisms. Given the broad scope of the topic and the interdisciplinary nature of the sources, a flexible yet rigorous search strategy was adopted.

4.1. Search Strategy

Relevant literature was retrieved between June 2024 and March 2025 using academic databases including PubMed, ScienceDirect, Google Scholar, and Cureus, among others. The search included peer-reviewed articles, clinical reviews, case reports, toxicology guidelines, and pharmacological

analyses. Additionally, institutional and governmental publications were included when clinically relevant. The following keywords and Boolean operators were used in various combinations: “neurotoxicity” OR “neurotoxic effects”; “drug-induced” OR “medication-induced” OR “chemotherapy-induced”; Specific drug classes or agents (e.g., “NSAIDs”, “antihistamines”, “fluoroquinolones”, “opioids”, “SSRIs”, “chemotherapy”, “beta-blockers”, “statins”); “mechanisms of neurotoxicity” OR “cognitive impairment” OR “peripheral neuropathy” OR “encephalopathy” OR “neuroinflammation”. Medical Subject Headings (MeSH terms) were applied where possible to enhance the specificity of the results.

4.2 Inclusion and Exclusion Criteria

Studies were considered eligible if they:

- Were published between 2000 and 2025.
- Were written in English.
- Investigated or reported neurotoxic effects of commonly prescribed or over-the-counter medications.
- Included human, animal, or in vitro models, as long as the findings were applicable to the understanding of human neurotoxicity.

Articles were excluded if they:

- Were purely anecdotal with no empirical data.
- Focused solely on illicit substances or experimental drugs not in regular clinical use.
- Were editorials or opinion pieces without reference to empirical evidence.

4.3 Data Extraction and Analysis

After an initial screening of titles and abstracts, full-text articles were assessed for relevance. References were manually reviewed and organized based on medication class and the type of neurotoxic effect reported. Studies were also categorized based on whether the neurotoxicity was linked to:

- Primary pharmacological action of the drug (e.g. inhibition of HMG-CoA reductase, proteosome inhibition)
- Secondary or off-target effects (e.g., mitochondrial dysfunction, oxidative stress)

The final selection comprised over 50 references, including both foundational pharmacology reviews and recent empirical studies. Particular attention was given to articles that included mechanistic insights, statistical outcomes, or clinically observed neurotoxic events.

5. Overview of Neurotoxic Effects in Common Medications

Understanding the neurotoxic effects of common medications is pivotal for enhancing patient safety and treatment efficacy. The subsequent sections delve into the mechanisms, risk factors, and clinical manifestations of neurotoxicity associated with various drug classes, including chemotherapy agents, cardiovascular medications, and psychiatric drugs. By exploring the interplay between pharmacological action and neurotoxicity, this examination aims to illuminate the complexities of medication management in clinical settings and its profound implications for patient care. These insights will serve as a foundation for informed decision-making in prescribing practices and highlight the necessity for individualized treatment approaches.

5.1 Definition and Classification of Neurotoxicity

Neurotoxicity is characterized as the capacity of certain chemical agents, particularly medications, to disrupt the structure and function of the nervous system, encompassing both the central and peripheral nervous systems. This disruption manifests in a wide array of symptoms, including cognitive impairments such as memory deficits, motor dysfunction like ataxia, and psychiatric disturbances like psychosis and mood disorders (Spencer & Lein, 2024, p. 727). The diversity of these clinical presentations underlines the need for vigilance in identifying neurotoxic agents in clinical practice to inform both diagnosis and intervention strategies.

The classification of neurotoxicity involves grouping agents by their mechanisms of action, which range from direct neuronal injuries to systemic changes causing inflammatory responses. For example, chemotherapy drugs like cisplatin are directly neurotoxic to neurons, whereas SSRIs disrupt synaptic neurotransmitter balance, affecting neuroplasticity (Bashir, Aziz & Noor, 2021, p. 821). This mechanistic categorization is essential for enabling targeted therapeutic interventions and precise monitoring strategies, as it facilitates a better understanding of the pathways through which neurotoxicity develops.

The temporal aspect of neurotoxic effects is another critical dimension of classification. Neurotoxic effects can either be acute, appearing shortly after exposure and including symptoms like encephalopathy and seizures, or chronic, developing over long-term usage and encompassing conditions such as neuropathy and cognitive decline. Cisplatin serves as a clear example, with sensory neuropathy affecting up to 85% of patients and persisting well beyond the treatment period (Bashir, Aziz & Noor, 2021, p. 823; Smyth et al., 2023, p. 120). Recognizing this dichotomy can help clinicians appropriately time neurological assessments and interventions to prevent long-term complications.

Patient-specific factors, including genetic predispositions such as polymorphisms in the CYP450 enzyme family and pre-existing conditions like renal impairment, have a substantial influence on the risk of developing neurotoxicity. Medications like anticholinergics, which require metabolic activation, demonstrate amplified neurotoxic effects in individuals with compromised metabolic or excretory pathways (Spencer & Lein, 2024, p. 727). This variability in risk necessitates a personalized approach to prescribing and monitoring, particularly for vulnerable populations with complex medical histories.

A unifying theme across different neurotoxic agents is the involvement of shared biological pathways, such as oxidative stress and apoptosis. For instance, bortezomib, a chemotherapeutic agent, induces apoptosis in neurons through oxidative stress, a mechanism also observed in cisplatin-induced mitochondrial dysfunction (Bashir, Aziz & Noor, 2021, p. 822). The identification of these common mechanistic pathways opens avenues for developing cross-cutting protective strategies, such as antioxidants or mitochondrial stabilizers, that could mitigate the neurotoxic effects of multiple drug classes.

Each class of neurotoxic drugs presents its own set of clinical manifestations, underscoring the importance of drug-specific classifications. For instance, anticholinergic drugs are strongly associated with cognitive impairments, while AEDs predominantly cause motor and balance dysfunction (Kufiah et al., 2019, p. 161; Urban, Navrátil & Pelclová, 2013, p. 25). Although anticholinergic neurotoxicity is reported in only 10% of patients, its impact on cognitive function is clinically significant, highlighting the necessity for cautious prescribing practices for at-risk populations.

Further refinements to classification systems account for variations in pharmacological profiles, such as lipophilicity and receptor selectivity. First-generation beta-blockers, which exhibit lower receptor specificity, are linked to a higher risk of neurotoxic side effects compared to newer, more selective agents (Lertvipapath & Warunyuwong, 2020, p. 3). Understanding these pharmacological nuances enables more informed decision-making, particularly when treating populations such as older adults, who may be more prone to central nervous system (CNS) side effects.

Clinical examples further demonstrate the relationship between drug dosage and neurotoxicity risk. High doses of glucocorticoids are linked to anxiety, mood disturbances, and seizures, with the severity of these neurological effects correlating directly with dose (Kufiah et al., 2019, p. 3). This underlines the importance of dose optimization in mitigating adverse outcomes and achieving therapeutic

efficacy with minimal risk.

The clinical manifestations and underlying mechanisms of neurotoxicity frequently overlap among agents, particularly in polypharmacy scenarios. For example, oxidative stress and inflammation are common pathways in the neurotoxic effects of both chemotherapy drugs and anticholinergics, making it challenging to attribute symptoms to a single causative agent (Bashir, Aziz & Noor, 2021, p. 823). These overlaps highlight the complexity of managing patients on multiple neurotoxic drugs and underscore the importance of an integrative diagnostic approach.

In recent years, there has been an effort to incorporate patient-centric variables, including genetic predisposition and environmental factors, into neurotoxicity classification systems. Such personalized approaches aim to predict and reduce risks more effectively, thereby improving overall treatment outcomes (Weimer, 2016, p. 1). This paradigm shift illustrates the growing emphasis on tailoring medical interventions to individual patient profiles.

The specificity of neurotoxic agents in targeting particular neuronal populations significantly influences their clinical impact. For example, heavy metals selectively affect dopaminergic neurons, leading to parkinsonism, while chemotherapy drugs frequently target sensory neurons, resulting in sensory neuropathies (Spencer & Lein, 2024, p. 727). Identifying these specific patterns of neuronal vulnerability is essential for developing targeted protective strategies to mitigate neurotoxic effects.

Dosage and patient-specific variables, such as genetic differences in drug-metabolizing enzymes, play a pivotal role in determining the extent of neurotoxicity. For instance, polymorphisms in the CYP450 enzyme family can significantly alter the metabolism of SSRIs, resulting in variable neurotoxic outcomes (Weimer, 2016, p. 1). This underscores the importance of advancing precision medicine to minimize individual risks and improve therapeutic safety.

The scope of neurotoxicity extends beyond pharmacological agents to include dietary supplements such as vitamin B6. Excessive intake of vitamin B6 has been linked to peripheral neuropathy, expanding the range of potential neurotoxic substances that require public awareness and regulatory oversight (Spencer & Lein, 2024, p. 727). This finding calls for stricter guidelines on supplement usage to prevent avoidable neurotoxic complications.

Advancements in imaging modalities, such as the use of magnetic resonance imaging (MRI) to detect leukoencephalopathy associated with methotrexate(MTX) neurotoxicity, have significantly enhanced

the ability to identify neurological damage early in its course (Kufiah et al., 2019, p. 2). Early detection technologies offer the potential for timely intervention, which could limit the progression of neurotoxic damage and improve patient outcomes.

Research focusing on overlapping mechanisms of neurotoxicity across drug classes, particularly on mitochondrial dysfunction, holds promise for identifying diagnostic markers and therapeutic targets. The involvement of mitochondrial pathways in the neurotoxicity of agents like cisplatin and SSRIs suggests that mitochondrial-protective agents could represent a valuable area for future drug development (Bashir, Aziz & Noor, 2021, p. 822). Such innovations offer hope for mitigating the widespread and diverse effects of neurotoxic medications.

In conclusion, the definition and classification of neurotoxicity encompass a complex interplay of clinical presentations, biological mechanisms, and patient-specific factors. This multi-faceted understanding provides a critical framework for improving diagnostic accuracy, therapeutic interventions, and patient outcomes in the context of neurotoxic drug effects

5.2 Mechanisms of Drug-Induced Neurotoxicity

Drug-induced neurotoxicity represents a significant concern in clinical practice, with oxidative stress emerging as a central mechanism underlying neuronal damage. Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defenses, which leads to damaging effects on lipids, proteins, and DNA. Doxorubicin (DXR), a chemotherapy agent, provides a clear example of this mechanism. It elevates malondialdehyde (MDA) – a biomarker of lipid peroxidation – while suppressing superoxide dismutase (SOD) activity, an essential antioxidant enzyme. This dual disruption results in impaired mitochondrial function, triggering neuronal apoptosis and further spreading cellular damage (Aldubayan et al., 2024, p. 805). Importantly, this mechanism is not unique to DXR but rather ubiquitous across many neurotoxic drugs, including SSRIs and other chemotherapeutic agents, making it a critical area for intervention. While antioxidant therapy has shown potential in preclinical studies, clinical trials are needed to validate the efficacy of such treatments in mitigating oxidative stress-induced neurotoxicity.

The role of mitochondria as regulators of cellular energy metabolism positions these organelles as primary targets of drug-induced oxidative damage. Cisplatin, another chemotherapy agent, exemplifies this by inducing mitochondrial dysfunction, which manifests as impaired ATP production and activation of apoptotic pathways. These disruptions translate clinically into sensory and

sensorimotor neuropathies, conditions that are reported in up to 85% of patients treated with cisplatin (Bashir, Aziz & Noor, 2021, p. 822). The intersection of oxidative stress and mitochondrial dysfunction is apparent in the compounded damage caused by drugs that disturb both processes. Furthermore, this damage is not limited to chemotherapy agents. Drugs targeting the CNS, like benzodiazepines, also contribute to mitochondrial dysfunction, with prolonged use resulting in swelling of mitochondria and diminished ATP synthesis, culminating in neurodegenerative changes. These findings suggest that therapies aimed at preserving mitochondrial integrity, such as the co-administration of mitochondria-protective antioxidants, could provide cross-cutting solutions for a spectrum of drug-induced neurotoxicities.

Neurotransmitter dysregulation constitutes another prominent mechanism contributing to the neurotoxic effects of commonly prescribed drugs. SSRIs such as fluoxetine and sertraline are well-documented in this context. The impact of fluoxetine on synaptic signaling in the hippocampus, characterized by variable effects on long-term potentiation (LTP), contrasts with sertraline, which inhibits LTP outright when administered alone. These disruptions impair neuroplasticity and memory processes, raising concerns about SSRIs' long-term effects on cognitive function and overall neurological health (Izumi et al., 2023, pp. 3-4). Additionally, neurotransmitter dysregulation can lead to significant motor side effects. SSRI-induced tardive dyskinesia and myoclonus, for example, illustrate the broader impact of altered synaptic signaling, affecting both cognitive and motor domains. Refining prescribing practices and exploring receptor-specific medications or selective sigma-1 receptor agonists could provide pathways to reduce these adverse outcomes, particularly in vulnerable populations.

Neuroinflammation has also been identified as a key driver of drug-induced neurotoxicity, with evidence linking inflammatory responses to neuronal damage and dysfunction. In the context of DXR-induced neuroinflammation, elevated levels of pro-inflammatory markers such as nuclear factor kappa B (NF-kB) and cyclooxygenase-2 (COX-2) amplify oxidative stress and apoptosis, thereby exacerbating neurotoxic effects (Aldubayan et al., 2024, p. 805). These inflammatory cascades are not isolated events but rather interconnected with oxidative stress and mitochondrial dysfunction, creating a feedback loop that compounds neuronal damage. Moreover, chemotherapy agents further aggravate neuroinflammation by disrupting the blood-brain barrier (BBB), permitting the infiltration of pro-inflammatory cytokines into the CNS. This phenomenon plays a critical role in conditions such as "chemo brain," where cognitive impairments are driven by cytokine-mediated neurotoxicity (Myers, Pierce & Pazdernik, 2008, p. 1). Anti-inflammatory therapies, including the use of dexamethasone to suppress neuroinflammatory markers, could serve as an actionable strategy to

mitigate these adverse effects in clinical settings.

Ion channel dysfunction and impaired electrical signaling in neurons represent another acute mechanism of drug-induced neurotoxicity. Fluoroquinolones, for instance, disrupt electrical activity at the neuromuscular junction, exacerbating pre-existing conditions such as myasthenia gravis and leading to symptoms like severe muscle weakness shortly after administration (Anwar et al., 2024, p. 2). This acute interference with neuronal excitability also manifests in seizures, a hallmark of ion-channel-related neurotoxicity. The direct impact of fluoroquinolones on ion channels underscores the urgency of developing targeted approaches to preserve ion channel integrity and prevent such neurotoxic episodes. Promising research into receptor antagonists, such as AMPA/kainate receptor inhibitors, has demonstrated potential in reducing seizure activity (Tsai & Lein, 2021, p. 50). These findings underscore the importance of targeted pharmacological treatments in mitigating ion channel disruption and its complications.

The disruption of acetylcholinesterase (AChE) activity represents a distinct and acute neurotoxic mechanism, particularly evident in organophosphate (OP) exposure. Acute inhibition of AChE activity by ≥60-70% induces a 'cholinergic crisis,' characterized by symptoms such as muscle weakness, respiratory depression, seizures, and potential mortality (Tsai & Lein, 2021, p. 49). Experimental evidence supports this mechanism, highlighting AChE inhibition as a primary driver of acute OP neurotoxic effects. Interestingly, even in the absence of AChE activity, neurotoxic symptoms persist, as demonstrated by AChE knockout mice displaying similar acute effects after OP exposure. This finding points to additional, AChE-independent pathways contributing to OP neurotoxicity, warranting further research. Persistent symptoms such as cognitive deficits and anxiety have been documented in patients long after AChE activity returns to baseline, emphasizing the importance of addressing both immediate and long-term neurotoxic outcomes (Tsai & Lein, 2021, p. 49). Novel therapeutic interventions, including the administration of receptor antagonists like LY293558, have shown promise in mitigating acute symptoms, such as seizures, underscoring the potential for targeted treatments (Tsai & Lein, 2021, p. 50).

Lastly, the integrity of the BBB plays a fundamental role in modulating the neurotoxic effects of systemic drugs. Medications like cisplatin and propofol have been shown to exert toxic effects on in vitro models of the BBB, indicating that their neurotoxic manifestations might be partially attributed to increased CNS exposure due to barrier disruption (Schultz et al., 2015, p. 147). This disruption not only facilitates the entry of systemically administered neurotoxic agents but also allows pro-inflammatory substances to infiltrate the brain, exacerbating neuronal damage. Strategies aimed at

enhancing BBB integrity, such as therapies targeting tight junction proteins, hold promise for reducing the CNS exposure to harmful agents. Similarly, minimizing the BBB permeability of neurotoxic drugs during their design phase could optimize their safety profiles and efficacy, thereby reducing the incidence of adverse outcomes.

In summary, mechanisms of drug-induced neurotoxicity comprise a complex interplay of oxidative stress, mitochondrial dysfunction, neurotransmitter dysregulation, neuroinflammation, ion channel interference, AChE inhibition, and BBB disruption. These pathways frequently overlap, compounding their neurotoxic effects and presenting significant clinical challenges, particularly in patients treated with neurotoxic drugs or experiencing polypharmacy. Understanding these mechanisms in detail provides critical insights into potential therapeutic interventions and highlights the necessity of developing targeted strategies to mitigate neurotoxicity across various drug classes.

5.3 Risk Factors and Susceptibility

Genetic predispositions play a critical role in influencing an individual's susceptibility to drug-induced neurotoxicity, largely by altering drug metabolism and transport mechanisms. Genetic variations in the cytochrome P450 (CYP450) enzyme family, for example, can significantly modify the metabolic processing of medications, leading to differential neurotoxic outcomes. Polymorphisms in specific genes such as CYP2D6 have been associated with reduced metabolism of certain drugs, including fluoxetine, which increases the risk of adverse neurological effects in individuals with these genetic variants (Weimer, 2016, p. 2). Similarly, polymorphisms in P-glycoprotein, a transporter protein responsible for drug efflux across the BBB, can result in elevated CNS exposure to neurotoxic agents, thereby amplifying their effects (Weimer, 2016, p. 1). These genetic influences underscore the importance of pharmacogenomic approaches in mitigating neurotoxicity, enabling clinicians to identify at-risk populations and adjust drug dosages or select alternative treatments accordingly. For instance, evidence linking certain HLA alleles with heightened neurological reactions to AEDs such as carbamazepine demonstrates the potential for genotype-based predictions of adverse drug reactions (Weimer, 2016, p. 2). However, while genetic testing offers considerable promise, its application remains limited by cost constraints and accessibility, necessitating the development of more practical strategies, such as population-based monitoring of common high-risk polymorphisms.

Patients with pre-existing conditions such as chronic kidney disease (CKD) are particularly vulnerable to drug-induced neurotoxicity due to impaired drug clearance and altered pharmacokinetics. Reduced renal function, characteristic of CKD, can cause the accumulation of

neurotoxic substances in the body, increasing the likelihood of adverse outcomes such as encephalopathy, confusion, and seizures. Baclofen, for instance, has been shown to induce neurotoxicity even at reduced doses in CKD patients, with studies reporting a prevalence of 7.0% in patients with severe CKD (Cheong et al., 2020, p. 1). This vulnerability highlights the necessity of careful dose adjustments in patients with CKD stages 4 and 5, where even minimal baclofen doses as low as 10 mg and 5 mg, respectively, may trigger neurotoxic effects (Cheong et al., 2020, p. 1). Additional conditions, such as liver dysfunction and pre-existing neurological disorders like myasthenia gravis, further exacerbate the neurotoxic risks associated with medications like fluoroquinolones or chemotherapy drugs such as cisplatin. For example, fluoroquinolones can aggravate myasthenia gravis within just one day of exposure, indicating a rapid and severe interaction between pre-existing neurological conditions and drug-induced neurotoxic mechanisms (Anwar et al., 2024, p. 2). A proactive approach involving careful drug selection and vigilant therapeutic monitoring is paramount for mitigating neurotoxicity in these vulnerable patient groups. Nonetheless, more research is needed to quantify the interaction between various comorbidities and neurotoxic agents to improve clinical decision-making.

Age is another fundamental determinant of susceptibility to drug-induced neurotoxicity. Older adults are particularly vulnerable due to physiological changes associated with aging, such as reduced renal and hepatic clearance, increased BBB permeability, and a general decline in protective mechanisms within the nervous system (Weimer, 2016, p. 1). These factors collectively heighten the neurotoxic risks of various medications, including fluoroquinolones, which are linked to neuropsychiatric events such as delirium and psychosis in elderly patients (Anwar et al., 2024, p. 2). Furthermore, polypharmacy, a common issue among older populations, significantly increases the potential for drug-drug interactions that amplify neurotoxic effects. For example, concurrent use of SSRIs and beta-blockers in geriatric patients has been associated with an increased risk of cognitive impairments, emotional dysregulation, and balance disturbances (Weimer, 2016, p. 2; Anwar et al., 2024, p. 2). Importantly, the subtle yet clinically significant cognitive changes often observed in older adults may be overlooked or misattributed to natural aging processes rather than drug-induced neurotoxicity, complicating timely diagnosis and intervention. Tailored strategies are essential for optimizing treatment outcomes in geriatric populations, such as conducting comprehensive medication reviews and prioritizing drugs with safer neurological profiles. For instance, hydrophilic beta-blockers like atenolol may be preferable over lipophilic agents like metoprolol to minimize CNS penetration and associated risks (Lertvipapath & Warunyuwong, 2020, p. 3). Nevertheless, current clinical approaches could benefit from greater integration of pharmacogenomic data to further enhance the precision of prescribing practices in older adults.

Polypharmacy represents a significant risk factor for drug-induced neurotoxicity, particularly in patients undergoing treatment with neurotoxic agents. Combining multiple neurotoxic drugs often intensifies adverse effects by compounding shared mechanisms such as oxidative stress and mitochondrial dysfunction. Chemotherapy regimens are an area of particular concern, as they often involve the use of multiple systemic agents. Nearly 43.8% of chemotherapy-treated lymphoma patients, for instance, develop polyneuropathy, with overlapping neurotoxic pathways further complicating symptom management (Bashir, Aziz & Noor, 2021, p. 1). Additionally, combining chemotherapeutic agents with CNS depressants exacerbates neuronal damage, contributing to severe peripheral neuropathies and diminished quality of life (Buduhan et al., 2018, p. 6). In palliative care settings, drug interactions involving beta-blockers and opioids have highlighted significant risks, including delirium and cognitive decline, as overlapping neurological pathways amplify adverse outcomes (Anwar et al., 2024, p. 5). Effective strategies to address polypharmacy require robust communication between healthcare teams, streamlined prescription practices, and the use of real-time drug interaction monitoring tools. However, such strategies are often difficult to implement in resource-constrained settings, underscoring the need for more accessible solutions to minimize the risks associated with polypharmacy.

The dosing and duration of drug exposure are critical factors in determining the likelihood and severity of neurotoxic effects. Prolonged use and high cumulative exposure to neurotoxic agents significantly elevate the risk of adverse neurological outcomes, as exemplified by cisplatin, where sensory and sensorimotor neuropathy affects up to 85% of patients following extended treatment (Bashir, Aziz & Noor, 2021, p. 2). Similarly, fluoroquinolones demonstrate a 3% increase in peripheral neuropathy risk with each additional day of exposure, underscoring the importance of limiting treatment durations to minimize long-term neurotoxic effects (Anwar et al., 2024, p. 2). Chronic NSAID usage is another example, with persistent oxidative stress and neuroinflammation linked to potential cognitive dysfunction over extended periods. To reduce neurotoxic risks, drug dosing protocols should account for individual factors such as body weight, age, and renal or hepatic function. While chemotherapy regimens often follow standardized dosing protocols, incorporating pharmacogenetic data to tailor these protocols based on cumulative exposure could significantly reduce adverse outcomes (Cheong et al., 2020, p. 1). However, balancing therapeutic efficacy with safety remains a significant clinical challenge, particularly for patients requiring long-term treatment.

Environmental and physiological factors, including the integrity of the BBB, also play a crucial role in modulating neurotoxic susceptibility. The BBB acts as a cruual barrier, protecting the CNS from

exposure to harmful drugs and substances. However, medications like cisplatin and fluoroquinolones can disrupt BBB integrity, leading to increased permeability and heightened neurotoxicity risks (Weimer, 2016, p. 1). Pathological conditions such as inflammation or head trauma further exacerbate BBB disruption, allowing pro-inflammatory cytokines and neurotoxic drugs to infiltrate the CNS. For instance, chemotherapy-induced neuroinflammation characterized by elevated cytokines and BBB disruption contributes significantly to long-term cognitive impairments such as chemo brain (Buduhan et al., 2018, pp. 1-3). Additionally, age-related increases in BBB permeability render older patients more susceptible to CNS adverse effects, particularly from lipophilic medications like beta-blockers (Anwar et al., 2024, p. 2). Preventative approaches to mitigate BBB-related risks include the development of targeted drug delivery systems and prioritizing drugs with limited BBB permeability. Recent advances in nanoparticle-based delivery systems for encapsulating chemotherapy agents offer promising potential for reducing CNS exposure and enhancing patient safety. However, these technologies remain in the early stages of development and require further validation through clinical trials.

In conclusion, risk factors and susceptibility to drug-induced neurotoxicity encompass a complex interplay of genetic, physiological, and environmental elements. A comprehensive understanding of these factors, combined with advancements in pharmacogenomics and targeted therapeutic strategies, is essential for improving patient outcomes and minimizing neurotoxic risks.

6. Cardiovascular Medications

The cardiovascular medications explored herein represent a vital intersection between therapeutic efficacy and potential neurotoxic side effects. From statins, which offer cholesterol-lowering benefits while posing risks for muscle-related symptoms and cognitive decline, to beta-blockers known for their neuropsychological implications, the complexities of these drugs underscore the importance of patient-centered prescribing practices. Furthermore, the implications of these medications on neurological health demand a thorough understanding of their mechanisms and patient-specific factors influencing treatment outcomes. As a critical component of this work, these discussions pave the way for a deeper consideration of how cardiovascular therapies can be optimized for safety and efficacy in patient care.

6.1 Statins

Statins, widely prescribed to manage hypercholesterolemia and reduce cardiovascular risks, are associated with a range of muscle-related side effects, commonly known as statin-associated muscle

symptoms (SAMS). A 2012 internet survey in the United States found that nearly 29% of statin users reported experiencing SAMSs, which can indirectly impact neurological health through systemic consequences such as reduced mobility and physical activity (Tournadre, 2020, p. 6). In patients with existing vulnerabilities, particularly elderly individuals, this reduction in physical activity may exacerbate cognitive decline and other neurological conditions over time. While SAMSs are primarily muscle-related, their secondary effects on neurological well-being emphasize the interconnectedness of physical and cognitive health and highlight the need for comprehensive management strategies in statin users.

The underlying mechanism of SAMSs involves mitochondrial dysfunction and impaired energy production in muscle cells, contributing to systemic oxidative stress. Although this mechanism does not directly target neurons, the elevated levels of ROS generated in statin-treated individuals may indirectly impact neuronal health (Calvo-Rodríguez, Núñez & Villalobos, 2015, p. 2). The spill-over effect of heightened oxidative stress emphasizes the need for further research to elucidate the potential neurological consequences of systemic oxidative imbalance in individuals on long-term statin therapy. This systemic effect raises concerns about the broader implications of mitochondrial dysfunction beyond muscle tissues.

Genetic predispositions also play a significant role in the development of SAMSs, with variations in the SLCO1B1 gene, responsible for statin metabolism, strongly associated with an increased risk of these side effects. Patients harboring these variations not only experience enhanced muscle-related symptoms but may also have an elevated risk of neurological complications due to prolonged statin exposure (Weimer, 2016, p. 1). These findings underscore the importance of personalized medicine in statin therapy, necessitating genetic screening to identify at-risk individuals and improve prescribing practices. However, the practical implementation of such screenings remains limited, requiring further integration into routine clinical practice.

The adverse effects associated with statins contribute to poor medication adherence, with only 54% of patients remaining compliant with therapy, often due to side effects like muscle pain and potential cognitive impairments (Tournadre, 2020, p. 6). Non-adherence significantly undermines the effectiveness of statin therapy in managing hypercholesterolemia, posing challenges to achieving long-term cardiovascular and neurological health. Strategies aimed at addressing these adherence issues, such as patient education and the development of statins with improved side effect profiles, must be prioritized to enhance treatment outcomes.

The potential impact of statins on cognitive function has been a topic of considerable debate. Hypotheses suggest that these effects may stem from statins' interference with cholesterol biosynthesis in the brain, a process integral to the production of myelin sheaths and synaptic structures critical for neuronal functioning (Weimer, 2016, p. 2). Reduced levels of brain cholesterol could disrupt signal transmission, potentially leading to memory loss, confusion, and even neurodegeneration. Given the controversy surrounding this topic, further longitudinal studies are essential to establish a clearer understanding of the relationship between statin use and cognitive outcomes.

The limited available research on the cognitive effects of statins has led to conflicting conclusions within the clinical community. While some population studies indicate a correlation between statin use and cognitive decline, others suggest potential protective effects due to the drugs' anti-inflammatory properties (Tournadre, 2020, pp. 4-6). This dichotomy underscores the need for targeted investigations focusing on specific patient demographics, statin dosages, and duration of treatment to resolve the ambiguity and guide clinical recommendations more effectively.

Emerging research suggests that the cognitive symptoms associated with statin use may exhibit region-specific effects in the brain, particularly in areas like the hippocampus, which is central to memory processing. This raises new questions about the role of individual neuroanatomical and functional variations in mediating these symptoms. Understanding such variations could pave the way for tailored therapeutic approaches and enhance the precision of statin prescribing practices.

One of the more severe complications linked to statin use is necrotizing autoimmune myopathy (NAM), a rare but significant condition affecting 45%-67% of cases with anti-HMGCR positivity (Tournadre, 2020, p. 11). Although NAM primarily impacts muscle tissue, it generates systemic inflammation and immune responses that may indirectly affect the CNS. These systemic effects could potentially exacerbate underlying neurodegenerative conditions or contribute to the development of new neurological impairments in affected patients.

The autoimmune nature of NAM underscores its potential to trigger broader systemic dysfunction. Inflammatory cytokines and immune complexes generated in response to muscle damage may cross the BBB, initiating or aggravating neuroinflammatory pathways (Weimer, 2016, p. 1). This raises significant concerns about the overlap between statin-induced muscle damage and potential CNS effects, further complicating the management of NAM and its associated risks.

Although NAM is a rare side effect, its progressive nature and the challenges it poses in treatment, often requiring immunosuppressive therapies, have considerable implications for long-term health outcomes. Affected individuals may require ongoing monitoring for both muscular and neurological complications, emphasizing the need for multidisciplinary approaches in managing this condition effectively.

Genetic polymorphisms in metabolic pathways, particularly those mediated by cytochrome P450 enzymes, play a crucial role in individual susceptibility to statin-induced neurotoxicity. Variations in these pathways can result in altered drug metabolism and increased statin accumulation, thereby amplifying the risks of cognitive and muscular symptoms (Weimer, 2016, p. 1). This underscores the necessity for a more personalized approach to statin therapy, incorporating pharmacogenetic insights to mitigate adverse effects and optimize treatment efficacy.

Patient-specific factors, such as pre-existing conditions including diabetes or chronic kidney disease, further compound the risk of neurotoxic effects. Impaired drug clearance in these populations heightens systemic exposure to statins, reducing the body's ability to compensate for disruptions in cholesterol biosynthesis in the brain (Cheong et al., 2020, p. 1; Al-Hasani, no date, p. 1). For example, chronic kidney disease not only slows drug metabolism but also amplifies the potential for adverse systemic effects, necessitating cautious dose adjustments in populations with compromised renal function.

The potential for genetic screening in predicting statin-related risks is supported by emerging evidence, although its integration into clinical practice remains limited. Implementing such screenings could help clinicians identify individuals at higher risk of adverse effects and tailor therapy accordingly, particularly in cases requiring long-term statin use. Further validation of these approaches through large-scale studies is needed to expand their adoption and effectiveness.

The dual impact of statins on oxidative stress presents a paradox in their role in neurotoxicity. While statins are known to reduce systemic inflammation and oxidative stress by lowering low-density lipoprotein (LDL) levels, they may also induce oxidative stress within mitochondria, disrupting neuronal energy production and contributing to neurodegeneration (Calvo-Rodríguez, Núñez & Villalobos, 2015, p. 2). This paradox accentuates the need for a nuanced understanding of statins' effects on oxidative balance and their implications for neurological health.

The mitochondrial dysfunction linked to statin-induced oxidative stress further illustrates its potential

role in apoptosis and neurodegeneration. Given the involvement of mitochondrial pathways in the neurotoxicity of several other drug classes, this mechanism warrants greater attention in the context of statins, particularly in vulnerable populations such as older adults.

Investigating the net effects of statins on neuronal oxidative stress and inflammation is critical to understanding their long-term neurotoxic profiles. While their cardiovascular benefits, such as reducing all-cause mortality by 10% and coronary events by 23%, are well established, their secondary neurological effects raise concerns about potential trade-offs (Tournadre, 2020, pp. 4-6). This highlights the importance of balancing therapeutic efficacy with safety in clinical management practices.

Despite their clear cardiovascular benefits, non-adherence to statin therapy remains a considerable challenge, largely due to side effects like SAMSs and cognitive impairments. These adherence issues compromise not only cardiovascular outcomes but also broader public health objectives aimed at reducing morbidity and mortality associated with hypercholesterolemia.

Addressing adherence challenges requires a deeper understanding of how side effect profiles influence patient behavior. Misattributions of age-related cognitive decline to statin use or vice versa may lead to premature discontinuation, underscoring the need for enhanced patient education and improved communication between healthcare providers and patients.

Balancing the therapeutic advantages of statins against their potential risks necessitates ongoing research into risk mitigation strategies. Approaches such as dose adjustments, alternative agents, or combination therapies could minimize neurotoxic risks while preserving cardiovascular efficacy, ultimately ensuring more individualized patient care.

6.2 Beta-Blockers

Beta-blockers, a commonly prescribed class of medications for cardiovascular conditions, are associated with numerous neuropsychiatric side effects, including depression, fatigue, and sleep disturbances. These effects are particularly prevalent in individuals using lipophilic beta-blockers, such as metoprolol, which have a high capacity to cross the BBB (Lertvipapath & Warunyuwong, 2020, p. 3). This property allows lipophilic beta-blockers to interfere significantly with CNS neurotransmitter activity, potentially amplifying their contribution to sleep-related disorders and fatigue. Such side effects are not only a clinical concern but may also impact patients' quality of life

and adherence to prescribed treatments. Hydrophilic beta-blockers, like nebivolol, demonstrate limited brain penetration and are therefore a safer alternative for patients vulnerable to central neuropsychiatric effects. These findings highlight the importance of individualizing beta-blocker choice based on the patient's unique characteristics to minimize adverse outcomes.

The link between fatigue and beta-blocker use is particularly pronounced in earlier-generation medications that lack receptor selectivity. These beta-blockers target both beta-1 and beta-2 adrenergic receptors non-specifically, leading to broader systemic effects, including excessive fatigue (Lertvipapath & Warunyuwong, 2020, p. 3). Newer beta-blockers, designed to be more selective for beta-1 adrenergic receptors, demonstrate improved tolerability and reduced side effects. For instance, the selective receptor activity of modern beta-blockers reduces their interference with other neurotransmitter systems, exemplifying advances in drug design aimed at minimizing adverse effects. Nonetheless, fatigue remains a challenge for certain patients, particularly those with pre-existing conditions, emphasizing the need for careful consideration of drug selection in clinical decision-making.

Depression is another neuropsychiatric concern associated with beta-blockers. This side effect has been linked to the modulation of norepinephrine and serotonin pathways, which play a critical role in regulating mood (Lertvipapath & Warunyuwong, 2020, p. 3). Lipophilic beta-blockers may have a stronger association with depressive symptoms due to their greater CNS penetration. However, interpretations of these findings remain complex, as existing mental health conditions or concurrent use of other neuroactive medications could also contribute to depression in this population. The inconclusive evidence highlights the need for further mechanistic studies to better understand the interaction between beta-blockers and mood regulation. Clinicians must remain vigilant in assessing mental health symptoms in patients prescribed beta-blockers, particularly in those with a history of depression.

Interference with sleep patterns is another notable side effect of beta-blockers, which can lead to broader implications for mental and physical health. Lipophilic beta-blockers, such as propranolol and metoprolol, can reduce melatonin synthesis, a hormone essential for maintaining circadian rhythms and sleep-wake cycles (Lertvipapath & Warunyuwong, 2020, p. 3). This interference not only causes sleep disturbances but may also exacerbate cognitive deficits and mood alterations, further complicating treatment for at-risk populations. On the other hand, hydrophilic beta-blockers like atenolol and nebivolol show minimal CNS penetration, making them preferable for individuals particularly susceptible to sleep-related issues. These considerations are significant for optimizing

patient outcomes, as disturbances in sleep can have cascading effects on overall health.

Pre-operative administration of beta-blockers has been associated with an elevated risk of post-operative delirium, with a 2.06 times higher likelihood compared to patients not using these medications (Lertvipapath & Warunyuwong, 2020, p. 3). This increased susceptibility likely stems from the effect of beta-blockers on cerebral perfusion and neurotransmitter activity during the physiological stress of surgery. Older adults are particularly vulnerable due to age-related declines in neurocognitive resilience and impaired drug clearance mechanisms. The interplay between surgical stress and beta-blocker-induced autonomic modulation creates a delicate balance that must be carefully managed to avoid exacerbating post-operative complications. Clinical strategies should prioritize dose adjustments and comprehensive pre-operative assessments to mitigate these risks effectively.

Delirium as a post-operative complication has been further linked to disruptions in the autonomic nervous system balance caused by beta-blockers. The exaggerated reduction in sympathetic nervous system activity, particularly during surgical stress, can impair the brain's adaptive responses (Lertvipapath & Warunyuwong, 2020, p. 3). This underscores the need for tailored dosing strategies and heightened monitoring, especially among patients with pre-existing cognitive decline or frailty. Specific attention should also be given to elderly patients, whose baseline vulnerabilities amplify the complexities of managing post-operative neuropsychiatric outcomes.

Earlier-generation beta-blockers exhibit a higher prevalence of neurotoxic side effects due to their non-selective receptor activity. In contrast, newer agents like bisoprolol and nebivolol demonstrate enhanced specificity for beta-1 adrenergic receptors, resulting in fewer systemic and central adverse effects (Lertvipapath & Warunyuwong, 2020, p. 3). This evolution in beta-blocker design reflects advancements in pharmacology aimed at preserving therapeutic efficacy while minimizing adverse outcomes. However, patient-specific considerations, such as existing comorbidities and age, remain critical in selecting the appropriate beta-blocker to optimize treatment benefits.

Interestingly, beta-blockers also exhibit therapeutic benefits in specific neuropsychiatric applications. For example, propranolol has demonstrated efficacy in managing emotional dysregulation and impulsivity at average doses of 106 mg/day, especially in patients requiring interventions for stress-induced behaviors (Lertvipapath & Warunyuwong, 2020, p. 3). This paradoxical role highlights the dual potential of beta-blockers as both therapeutic agents and contributors to neuropsychiatric side effects. Therefore, their use in these contexts requires meticulous monitoring to balance the intended

therapeutic outcomes against the risk of adverse effects such as cognitive disturbances.

The concurrent use of beta-blockers with other medications, particularly those affecting the CNS, can significantly amplify neurotoxic risks. For example, combining beta-blockers with opioids in palliative care has been correlated with an increased likelihood of cognitive impairment and delirium (U.T. M.D. Anderson Cancer Center, 2024, p. 5). These risks underscore the need for thorough medication reviews and close collaboration among healthcare providers to manage polypharmacy effectively. In complex pharmacological regimens, identifying and mitigating overlapping mechanisms of neurotoxicity is essential, particularly in older adults and individuals with neurological vulnerabilities.

Chronic beta-blocker use has been shown to disrupt the autonomic nervous system's balance over time, potentially diminishing the brain's ability to adapt to physiological stress. Prolonged modulation of neurotransmitter systems may contribute to reduced cognitive resilience, particularly in individuals with underlying neurological conditions (U.T. M.D. Anderson Cancer Center, 2024, p. 5). Individualized treatment plans, including periodic evaluations of neurological function, are vital for mitigating these long-term risks and ensuring sustainable therapeutic outcomes.

The neurotoxic risks associated with beta-blockers highlight the importance of balancing their potential adverse effects against their clinical benefits. Patient-specific factors such as age, pre-existing conditions, and lifestyle must guide medication selection and dosing strategies. For instance, lipophilic beta-blockers may be avoided in patients at risk of CNS side effects, while hydrophilic options can be preferred for these populations. Tailored approaches incorporating regular monitoring and patient education are essential for minimizing neurotoxic risks and optimizing overall health outcomes.

7. Gastrointestinal and Anti-Inflammatory Drugs

The exploration of gastrointestinal and anti-inflammatory medications reveals a complex interplay between therapeutic benefits and neurotoxic risks. Each section delves into specific drug classes, such as PPIs, NSAIDs, and antihistamines, highlighting their potential neurotoxic effects and the underlying mechanisms driving these complications. By analyzing the adverse neurological outcomes associated with these widely used agents, the discussion underscores the importance of careful prescription practices and patient monitoring in optimizing treatment while minimizing harm. This analysis contributes to the overarching theme of this work, which emphasizes the critical need for

awareness and individualized approaches in medication management to enhance patient safety and treatment efficacy.

7.1 Proton Pump Inhibitors

Proton pump inhibitors (PPIs), widely utilized to manage conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers, have been increasingly associated with potential neurotoxic effects, particularly cognitive impairment and dementia. These effects are thought to result from disruptions in neurotransmitter systems caused by prolonged PPI use (Kufiah et al., 2019, p. 2). Cognitive dysfunction in PPI users may arise from altered availability of neurotransmitters like acetylcholine, a critical component for neuronal communication. The suppression of proton pumps, along with those in extra-gastric tissues, can interfere with neurochemical pathways, potentially impairing neuronal signaling and leading to memory deficits or confusion. Population-based studies have revealed a higher prevalence of dementia and cognitive decline among long-term PPI users, though contrasting evidence suggests that age and comorbidities such as chronic illnesses may confound these associations. The exact contribution of PPIs to dementia risk, therefore, remains controversial and warrants further investigation. Older individuals may face heightened susceptibility to these effects due to reduced metabolic drug clearance and pre-existing declines in neurological reserve, which amplify their vulnerability. This underscores the critical need for careful evaluation of PPI use in older adults and the implementation of regular cognitive monitoring.

Recent studies have implicated PPIs in vitamin B12 deficiency, a condition essential for neurological health, as another potential pathway leading to neurotoxic effects (Weimer, 2016, p. 2; Kufiah et al., 2019, p. 2). PPIs inhibit gastric acid secretion, a process necessary for adequate absorption of vitamin B12 through its interaction with intrinsic factor, which requires an acidic environment to function properly. Chronic B12 deficiency may result in the demyelination of central and peripheral nerves, an outcome with symptoms ranging from memory loss to paraesthesia and, in severe cases, irreversible neurological damage. Observational research consistently reports a higher prevalence of vitamin B12 deficiency among chronic PPI users, further supporting this association. Additionally, elevated homocysteine levels due to vitamin B12 deficiency, known to exert neurotoxic effects and cause endothelial damage, link PPIs indirectly to cognitive impairments and neurological harm. Proactive mitigation strategies, such as regular monitoring of serum B12 levels and supplementation where needed, are crucial, particularly for at-risk populations like older adults and individuals with malabsorption syndromes.

The mechanisms underlying PPI-induced neurotoxicity may extend beyond vitamin B12 deficiencies, involving alterations in brain metabolism and the inhibition of H+/K+ ATPase enzymes found in extra-gastric tissues (Gibler, 2015, p. 3). These enzymes, present in the brain, play a role in maintaining cellular pH balance and ion homeostasis, and their suppression may disrupt neuronal activity. Furthermore, the gut-brain axis appears to mediate another potential mechanism, as altered gastric acid secretion from PPI use affects gut microbiota diversity. Dysbiosis in the gut microbiota can lead to the production of neuroactive metabolites and inflammatory cytokines capable of crossing the BBB. Experimental evidence suggests that prolonged PPI use decreases gut microbiota diversity and increases neuroinflammatory markers, establishing a plausible link between PPIs and cognitive changes. Future investigations into the extra-gastric effects of PPIs and their influence on gut-brain axis interactions could refine our understanding of their neurotoxic risks, potentially guiding the development of PPIs with reduced systemic effects.

Evidence from clinical research highlights higher rates of adverse drug reactions (ADRs) in PPI users compared to other gastrointestinal agents, with neurological complications such as confusion and delirium being frequently reported in hospitalized patients (Schatz & Weber, 2015, p. 5). These symptoms may result from pharmacodynamic interactions affecting CNS function, including heightened neuroinflammatory responses or disruptions in neurotransmitter signaling. Confusion and altered cognition are particularly prevalent in populations with complex drug regimens or diminished physiological reserves, such as critically ill or older adults. Systematic reviews have further noted that PPI-related neurological ADRs are dose-dependent, with higher doses or prolonged use correlating with more severe cognitive deficits. These findings urgently call for strategies such as dose reductions, short-term therapy, and multidisciplinary medication reviews to minimize risks, particularly in hospitalized and vulnerable populations. Enhanced cognitive monitoring combined with timely interventions could greatly improve patient outcomes.

Another significant adverse effect associated with chronic PPI use is hypomagnesemia, a condition marked by reduced magnesium levels, which can cause seizures, dizziness, and cognitive changes (Weimer, 2016, p. 2; Gibler, 2015, p. 4). By interfering with magnesium absorption through the inhibition of cellular transporters such as TRPM6 and TRPM7 channels, PPIs contribute to systemic magnesium depletion. Magnesium is vital for maintaining neuronal excitability and ionic balance, and its deficiency may lead to excitotoxicity and oxidative damage in the nervous system. Clinical data revealing an increased incidence of hypomagnesemia among long-term PPI users underscore the severity of this issue, with severe cases sometimes requiring hospitalization and electrolyte correction. Fortunately, hypomagnesemia-related neurological symptoms are often reversible with

magnesium supplementation, highlighting the importance of routine monitoring and proactive management in chronic PPI users. Increased awareness among healthcare providers regarding this risk could drive the adoption of diagnostic screenings and early intervention strategies.

PPI-related risks may also vary significantly between individuals due to genetic predispositions and concurrent drug use (Anwar et al., 2024, p. 2). Genetic polymorphisms in CYP2C19, an enzyme critical for PPI metabolism, influence drug pharmacokinetics. Poor metabolizers experience prolonged drug exposure, thereby facing higher risks of adverse effects, including neurotoxicity. Concurrent use of medications impacting CNS function or electrolyte balance, such as diuretics, further amplifies these risks. These compounding factors highlight the importance of personalized treatment plans. Vulnerable populations, particularly older adults with compromised renal function or polypharmacy regimens, necessitate tailored dosing strategies. Beginning therapy with lower doses or limiting treatment duration could reduce neurotoxic risks while preserving therapeutic efficacy. Additionally, pharmacogenomic research has the potential to inform patient-specific responses to PPIs, enabling clinicians to predict and prevent neurotoxic outcomes effectively.

In conclusion, the neurotoxic effects of PPIs represent a growing area of clinical concern, underscoring the importance of balancing their gastrointestinal benefits with potential neurological risks. By adopting personalized approaches, incorporating genetic insights, and ensuring thorough patient monitoring, healthcare providers can mitigate these risks and optimize therapeutic outcomes for PPI users.

7.2 Non-Steroidal Anti-Inflammatory Drugs

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for their analgesic and anti-inflammatory properties, but their potential neurotoxic effects have raised significant clinical concerns. One of the primary pathways of NSAID-induced neurotoxicity is through their impact on the gastrointestinal mucosa, leading to complications such as enteropathy and colopathy. These conditions, which comprise approximately 40% of NSAID-related complications, compromise systemic health by increasing gut permeability, allowing the translocation of pro-inflammatory cytokines and bacterial endotoxins into the bloodstream (Hnepa et al., 2021, p. 2). Once in circulation, these inflammatory mediators can cross the BBB and contribute to gut-brain axis dysfunction. This disruption has implications for neurological health, as neuroinflammation triggered by systemic factors is increasingly recognized as a precursor to neurodegenerative diseases. Further research is essential to understand the mechanisms underlying this gut-brain interaction and to determine

strategies for mitigating the neurological consequences of chronic NSAID use.

The chronic gastrointestinal damage induced by NSAIDs, such as gastric and duodenal ulcers seen in up to 40% of cases, significantly impacts nutrient absorption (Hnepa et al., 2021, p. 3). Nutrients essential for neuroprotection, including B vitamins and minerals like magnesium, are particularly affected, leading to deficiencies that exacerbate neurological decline. This malabsorption poses a dual risk, not only impairing systemic health but also directly influencing neuronal function. For instance, deficiencies in B-complex vitamins are closely linked to cognitive impairment and an increased risk of neurodegenerative conditions. The extensive use of NSAIDs among older adults, a demographic already vulnerable to nutrient deficiencies, highlights the urgent need for interdisciplinary approaches to care, addressing both gastrointestinal and neurological health.

Emerging evidence points to the potential role of microglial activation in NSAID-induced neurotoxicity, a process indirectly triggered by enteropathy-related systemic inflammation. Microglia, the brain's resident immune cells, are known to become hyperactivated in response to heightened levels of systemic inflammatory mediators, disrupting neuronal homeostasis and increasing the risk of neurodegenerative processes. Although this mechanism remains underexplored, studies suggest that the activation of microglia represents a critical link between systemic inflammation and CNS damage. Validating these pathways through targeted research could inform the development of drugs that minimize systemic inflammatory effects while retaining NSAIDs' therapeutic benefits.

The association between chronic NSAID use and cognitive dysfunction has raised concerns about the drugs' potential role in oxidative stress and inflammation within the nervous system. Prolonged use of NSAIDs is known to elevate ROS levels, which can directly damage neuronal membranes, disrupt synaptic function, and lead to neurodegeneration. These effects are particularly concerning in older adults, who are frequently prescribed NSAIDs and may have pre-existing vulnerabilities to oxidative stress. Animal studies demonstrating memory impairments and cognitive decline in the context of elevated ROS levels underscore the need for further translational research to assess the relevance of these findings in clinical populations. Additionally, identifying therapeutic interventions to counteract oxidative damage could mitigate cognitive risks associated with long-term NSAID use.

NSAIDs influence the production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukins, which are capable of crossing the BBB and inducing neuroinflammation. These cytokines have been implicated in the pathology of neurodegenerative conditions such as

Alzheimer’s disease, providing a plausible explanation for the cognitive dysfunction observed with chronic NSAID use (Bruhns et al., 2018, p. 2). However, NSAIDs exhibit paradoxical effects on neuroinflammation; while they may contribute to systemic inflammation, certain NSAIDs also demonstrate anti-inflammatory properties in neurological contexts. For example, their potential role in reducing amyloid-beta deposition in Alzheimer’s disease complicates the evaluation of their overall impact on cognitive health. These conflicting properties necessitate a nuanced understanding of NSAIDs' dual effects and tailored approaches to their prescription.

Magnesium deficiencies, often resulting from NSAID-induced gastrointestinal disruptions, are another factor contributing to the neurotoxic effects of these medications. Magnesium is critical for maintaining neuronal excitability, regulating ion channels, and supporting mitochondrial function. Hypomagnesemia, a condition linked to seizure activity, dizziness, and cognitive changes, is frequently observed in long-term NSAID users due to impaired absorption mechanisms (Hnepa et al., 2021, p. 3). Severe cases may lead to excitotoxicity and oxidative damage in the nervous system, underscoring the systemic implications of NSAID-induced electrolyte imbalances. Routine monitoring of magnesium levels and timely supplementation could be effective strategies to manage these risks and improve patient outcomes, particularly in populations susceptible to electrolyte disturbances.

The cognitive symptoms of hypomagnesemia extend beyond seizure susceptibility to include memory deficits and confusion, further illustrating the interconnectedness of systemic factors and neurological health. Clinical evidence demonstrates that magnesium supplementation can mitigate these symptoms, providing an actionable approach to reducing the neurotoxic effects of NSAIDs. However, further research is needed to determine the optimal strategies for prevention and management, particularly in high-risk populations such as older adults and those with pre-existing neurological conditions.

Despite the neurotoxic risks associated with NSAIDs, their anti-inflammatory properties have led to their exploration as potential neuroprotective agents in conditions such as Alzheimer’s disease. Experimental studies suggest that NSAIDs may reduce neuroinflammation and amyloid-beta plaque formation, two hallmarks of Alzheimer’s pathology (Kawade & Hedaoo, 2019, pp. 448-450). However, the clinical translation of these findings remains limited, with conflicting evidence from human studies raising questions about the balance of neuroprotective versus neurotoxic effects. Novel administration methods, such as nasal delivery systems, have been proposed to bypass systemic side effects while targeting central neuroinflammation directly. Although promising, these approaches are

still in their infancy, requiring extensive clinical validation to assess their safety and efficacy.

The dual effects of NSAIDs on neuroprotection and neurotoxicity highlight the importance of individualized treatment plans that balance benefits against risks. For instance, dosing strategies and patient-specific factors, such as genetic predispositions and comorbidities, play a critical role in determining outcomes. Advanced pharmacogenomic research could enable the identification of individuals at high risk of neurotoxic effects, guiding personalized interventions. For populations with an elevated susceptibility to neurotoxicity, alternative therapeutic agents or combination therapies may offer safer and equally effective options.

The adverse CNS effects of NSAIDs, which include headache, confusion, and dizziness, are primarily linked to disruptions in prostaglandin synthesis. Prostaglandins play a crucial role in neuronal signaling, and their inhibition by NSAIDs can increase neuronal sensitivity to excitotoxic damage (Kamath, 2013, p. 2). This disruption extends to ion channel regulation, an essential component of synaptic transmission, potentially explaining the neurological symptoms observed in chronic NSAID users. Tailored treatment approaches that minimize these risks, such as selective inhibition of specific prostaglandin pathways, represent an area for further pharmacological innovation.

The neurotoxic risks of NSAIDs are particularly pronounced in populations with pre-existing conditions, such as epilepsy or migraine, which heighten susceptibility to adverse outcomes. For these individuals, tailored prescriptions that account for both the therapeutic benefits and potential neurological risks of NSAIDs are critical. Enhanced patient education and interdisciplinary care strategies could further mitigate risks and optimize treatment outcomes.

NSAIDs are widely used, particularly among older adults, with more than 70% of individuals over the age of 65 taking these medications weekly (Hnepa et al., 2021, p. 1). This demographic is uniquely vulnerable to the neurotoxic risks of NSAIDs due to age-related declines in drug clearance capacities and cumulative exposure. Polypharmacy, another prevalent issue in older populations, compounds these risks by increasing the likelihood of pharmacokinetic and pharmacodynamic interactions. Regular medication reviews and comprehensive care plans are essential for addressing these challenges and reducing the overall neurotoxic burden.

Polypharmacy involving NSAIDs and other neurotoxic medications, such as CNS depressants, significantly increases the likelihood of adverse neurological outcomes. The overlapping mechanisms of neurotoxicity in these drug classes complicate treatment strategies, particularly in older adults or

those with compromised neurological resilience. Collaborative healthcare approaches that include regular screening for drug interactions and patient-specific risk factors are vital for mitigating these compounded risks.

Individual susceptibility to NSAID-induced neurotoxicity is influenced by genetic predispositions, such as polymorphisms in drug-metabolizing enzymes. Variations in these pathways can lead to altered drug metabolism and heightened neurotoxic effects. Incorporating genomic insights into NSAID prescribing practices could enable the identification and protection of at-risk individuals, though broader integration of these approaches into routine clinical practice remains a challenge.

Despite their widespread use and therapeutic benefits, NSAIDs' neurotoxic risks are underexplored, particularly in at-risk populations. Greater interdisciplinary research is needed to elucidate the long-term neurological consequences of chronic NSAID use and to develop safer prescribing practices. By balancing risks and benefits and adopting personalized approaches to care, it is possible to optimize outcomes for NSAID users while minimizing adverse neurological effects.

7.3 Antihistamines

Antihistamines are widely used for their therapeutic effects in managing allergic conditions, yet their neurotoxic side effects, particularly those associated with first-generation antihistamines, are a growing concern in clinical practice. These neurotoxic effects predominantly result from their ability to cross the BBB and block histaminergic H1 receptors in the CNS, leading to significant sedative properties. Drugs such as promethazine, diphenhydramine, and hydroxyzine are known for their pronounced sedative effects, which, while beneficial in specific contexts such as preoperative anxiety management or postoperative analgesia, limit their applicability in scenarios requiring cognitive and psychomotor clarity. The high lipid solubility of first-generation antihistamines enhances their CNS penetration, exacerbating side effects such as drowsiness and impairments in concentration. Consequently, their use in cognitively or physically demanding activities, such as operating machinery or driving, poses considerable risks. As studies have demonstrated, the sixfold increase in traffic accident risk among users of sedating antihistamines underscores their significant impact on public safety and highlights the importance of prescribing these medications judiciously (Popescu, 2008, pp. 3-4).

The impairments in cognitive alertness and psychomotor speed induced by first-generation antihistamines are dose-dependent, with even therapeutic doses contributing to significant functional

deficits. These neurotoxic effects render their long-term use problematic in scenarios where mental clarity is essential. Experimental real-driving tests confirm that repeated daily dosing of these drugs leads to substantial deficits in driving ability and reaction times, further illustrating their cumulative impact on cognitive and psychomotor performance (Popescu, 2008, pp. 3-4). In contrast, non-sedating antihistamines such as cetirizine offer effective therapeutic outcomes with negligible disruption to alertness and psychomotor abilities. Cetirizine represents a significant advancement in pharmacological innovation, specifically designed to avoid CNS penetration while maintaining antihistaminic efficacy (Khilnani, Khilnani & Thaddanee, 2020, p. 2). Despite this progress, individual responses to treatment and the potential for mild CNS effects in certain populations indicate the necessity for continued monitoring and individualized therapeutic approaches.

First-generation antihistamines are also linked to severe cardiac and neurological complications due to their ability to block potassium channels, which prolongs the QTc interval. This effect on ion channel activity increases the risk of life-threatening ventricular arrhythmias, particularly in cases of overdose. Drugs such as cyproheptadine, diphenhydramine, and promethazine exemplify this risk, which is further magnified in individuals with pre-existing cardiac conditions or kidney dysfunction. The interplay between cardiac and neurological health underscores the systemic risks of first-generation antihistamines, emphasizing the need for comprehensive assessments before prescribing these medications (Khilnani, Khilnani & Thaddanee, 2020, p. 7). In contrast, second-generation antihistamines like cetirizine demonstrate a preferable safety profile by avoiding the prolongation of the QTc interval, thus mitigating the associated risks of arrhythmias and CNS impairment. These differences highlight the critical role of pharmacological design in reducing systemic toxicity while maintaining therapeutic efficacy.

Advances in the development of non-sedating antihistamines (NSAHs) have significantly reduced the neurotoxic risks associated with traditional first-generation agents. By minimizing BBB penetration, NSAHs such as cetirizine achieve therapeutic outcomes without causing drowsiness, psychomotor impairments, or attention deficits (Khilnani, Khilnani & Thaddanee, 2020, p. 2). This pharmacological innovation has made NSAHs the preferred treatment for individuals requiring cognitive clarity while managing allergic conditions. Additionally, their improved safety profile compared to first-generation antihistamines reflects ongoing progress in drug development aimed at reducing systemic toxicity. However, even NSAHs require cautious use in polypharmacy contexts, as interactions with other CNS-active medications may elevate neurotoxic risks. These considerations underscore the importance of vigilance in clinical decision-making and the need for patient-specific treatment plans.

The neurotoxic risks of antihistamines are particularly pronounced in vulnerable populations, such as older adults and individuals on polypharmacy regimens. Age-related changes in drug metabolism, including reduced renal clearance, increase the sensitivity of older adults to the cognitive and sedative effects of first-generation antihistamines. These pharmacokinetic alterations, combined with the complexities of polypharmacy, amplify the frequency and severity of adverse outcomes such as confusion, delirium, and cognitive decline in these populations (Anwar et al., 2024, p. 2). Tailored dosing strategies, alongside the preference for non-sedating options, offer practical solutions to minimize these risks. Guidelines that emphasize lower dosages, periodic monitoring, and alternative treatments can improve safety and therapeutic outcomes for at-risk populations.

In conclusion, while first-generation antihistamines remain effective for specific therapeutic indications, their neurotoxic effects and systemic risks significantly restrict their broader utility. The introduction of non-sedating antihistamines has addressed many of these concerns, reflecting advancements in pharmacological innovation. However, further research is needed to explore the long-term systemic effects of antihistamines and to optimize personalized treatment approaches that balance therapeutic benefits with safety.

8. Psychiatric and Neurological Medications

The intricate relationship between psychiatric and neurological medications and their neurotoxic effects underscores the urgent need for heightened awareness in clinical practice. This section delves into the diverse pharmacological classes, including SSRIs, AEDs, and fluoroquinolones, highlighting their mechanisms of action, associated risks, and the implications for patient safety and treatment efficacy. By examining the nuances of these medications, a clearer understanding of their impact on cognitive function and overall neurological health emerges, paving the way for informed decision-making and personalized therapeutic strategies in patient care.

8.1 Selective Serotonin Reuptake Inhibitors

Selective serotonin reuptake inhibitors (SSRIs) are a widely prescribed class of medications used primarily in the treatment of depression and anxiety disorders. They have been shown to modulate neuroplasticity and memory through complex mechanisms involving sigma-1 receptors and neurosteroids, which are critical to their therapeutic and neuroprotective effects. Research by Izumi et al. (2023, p. 3) demonstrates that fluvoxamine, at a concentration of 1 μM, can overcome the inhibition of LTP caused by lipopolysaccharide (LPS), provided the drug is administered before and

during LPS exposure. This indicates fluvoxamine's potential in stabilizing hippocampal function under inflammatory conditions. The ability of SSRIs to interact with sigma-1 receptors facilitates the production of neurosteroids, such as allopregnanolone, which play a significant role in enhancing synaptic plasticity and reducing neuroinflammation. These findings underscore the centrality of the hippocampus in therapeutic outcomes, given its role in learning and memory, as well as its vulnerability to inflammatory damage. However, the timing of fluvoxamine administration appears to be critical, suggesting that the protective effects of SSRIs might be optimized in specific clinical scenarios. This warrants further exploration into the temporal dynamics of SSRI interventions to maximize their neuroprotective potential.

The differential effects of SSRIs on LTP and inflammation-induced neuroplasticity disruptions highlight notable variability in their neuroprotective mechanisms. For instance, fluoxetine at a higher concentration of 3 μM completely negates the effects of LPS on LTP, whereas fluvoxamine operates effectively only under specific conditions (Izumi et al., 2023, pp. 3-4). This underscores the variability in the pharmacodynamics of SSRIs, with fluoxetine demonstrating a stronger capacity to counteract inflammatory processes compared to fluvoxamine. The dose-dependent efficacy of these drugs suggests that their clinical application must be personalized, taking into account the inflammatory context and patient-specific factors. Additionally, the contrasting neuroprotective profiles of these two SSRIs provide a compelling case for further comparative studies to delineate their distinct molecular pathways. Such investigations could inform personalized treatment strategies, optimizing outcomes for conditions involving neuroinflammation and cognitive deficits.

Despite their benefits, SSRIs present risks of neurotoxic effects, including movement disorders such as akathisia, myoclonus, and tardive dyskinesias, which may range from mild to severe (Duma & Fung, 2019, p. 56). Akathisia, for example, can emerge from disruptions in the serotonin-dopamine equilibrium that affect basal ganglia function. Chronic movement disorders like tardive dyskinesias, on the other hand, may result from long-term receptor desensitization or upregulation. These neurotoxic effects highlight the necessity of closely monitoring patients undergoing SSRI therapy, particularly those with pre-existing neurological conditions or concurrent medication use. The variability in the onset and severity of these symptoms further suggests that certain populations may be more predisposed to these adverse effects. This calls for the development of standardized protocols for evaluating motor function in patients on long-term SSRI therapy, alongside tailored adjustments to minimize neurotoxic risks.

Data from toxicological services further reveal a significant rise in SSRI-related toxicological cases,

increasing by 1347.4% over a 15-year period, with lethality rates of only 1.6% compared to other CNS drugs (Urban, Navrátil & Pelclová, 2013, p. 1). This dramatic increase in reports reflects both the widespread use of SSRIs and the growing recognition of their potential misuse and overdose risks. The relatively low lethality rates are likely attributable to the favorable safety profiles of SSRIs, which exhibit higher therapeutic indices compared to other CNS medications. Nonetheless, the magnitude of reported cases underscores the need for heightened public and clinical awareness regarding the dangers of improper use. Preventative strategies, such as patient education on dosage adherence and the early recognition of overdose symptoms, are critical. Furthermore, healthcare systems should consider integrating routine checks during follow-up consultations to reduce the likelihood of misuse and monitor potential toxicological outcomes efficiently.

Another serious adverse effect associated with SSRIs is serotonin syndrome, which manifests as CNS excitability, movement disorders, and autonomic instability (Duma and Fung, 2019, p. 56). This condition is often caused by an acute imbalance in serotonin levels, typically from SSRI overdose or interactions with other serotonergic agents. The clinical presentation of serotonin syndrome includes hyperreflexia, altered mental status, and autonomic disruptions, which can escalate to severe complications such as seizures or coma if left untreated. Early identification and intervention are therefore critical. Preventative measures must involve careful prescribing practices, clear communication of potential risks, and vigilant monitoring, especially in patients undergoing polypharmacy. Guidelines for dose tapering or discontinuation in high-risk scenarios should also be standardized to further mitigate the risk of serotonin syndrome in clinical settings.

Elderly patients and those on complex polypharmacy regimens represent particularly vulnerable populations for SSRI-induced neurotoxicity, necessitating individualized prescription strategies (Anwar et al., 2024, p. 2). Age-related declines in hepatic metabolism and renal clearance increase the likelihood of adverse effects, as does the higher propensity for drug-drug interactions in polypharmacy contexts. These vulnerabilities necessitate adjustments in dosing regimens and an enhanced focus on patient-specific health profiles, including comorbidities and concurrent medications. Pharmacogenomic testing could serve as a valuable tool to predict individual responses to SSRIs, offering clinicians the means to tailor treatment plans effectively. This approach could reduce adverse outcomes while maintaining therapeutic efficacy, addressing the unique needs of at-risk populations.

In conclusion, SSRIs remain a cornerstone of psychiatric treatment but present a complex interplay of therapeutic benefits and neurotoxic risks. While their role in modulating neuroplasticity and

counteracting inflammation underscores their utility, the potential for movement disorders, serotonin syndrome, and toxicological concerns demands careful consideration. Optimizing SSRI use requires a patient-centered approach that integrates personalized dosing, vigilant monitoring, and further investigation into their differential pharmacodynamics.

8.2 Anti-Epileptics

Antiepileptic drugs (AEDs) are integral to epilepsy management but are often accompanied by significant neuropsychological side effects, including cognitive impairments such as memory dysfunction, attention deficits, and reduced executive functioning. These adverse effects are frequently dose-dependent, with higher doses exacerbating the risk of cognitive decline. Clinical research indicates that polytherapy, where multiple AEDs are administered simultaneously, further compounds these negative cognitive outcomes compared to monotherapy. For instance, patients on polytherapy often report challenges in maintaining focus and processing information, highlighting the interplay between drug load and cognitive performance. The mechanisms underlying these impairments include the disruption of ion channel function and synaptic modulation, illustrating the trade-off between seizure control and neuropsychological health (Hansen, Finzel and Block, 2010, p. 1). These findings emphasize the importance of individualizing AED regimens to balance efficacy with cognitive safety.

The cognitive impact of AEDs is closely tied to their pharmacological properties, with variations observed across different medications. Notably, drugs such as carbamazepine and phenytoin, which operate through sodium channel blockade, are significantly associated with cognitive impairments. This mechanism interferes with normal neuronal signaling and synaptic plasticity, contributing to long-term cognitive decline (Weimer, 2016, p. 2). Similarly, topiramate and zonisamide's effects on carbonic anhydrase inhibition disrupt critical neuronal processes, leading to pronounced cognitive dysfunctions. In contrast, newer AEDs like lamotrigine appear to have safer cognitive profiles, offering options for patients who require long-term therapy. These distinctions underscore the necessity for clinicians to carefully evaluate the pharmacodynamics of AEDs before prescribing, particularly for individuals with pre-existing cognitive vulnerabilities. Proactive monitoring and adjustments can help mitigate these risks, ensuring a more favorable balance between therapeutic outcomes and side effects.

Individual susceptibility significantly influences the extent of cognitive side effects from AED use. Factors such as age, genetic predisposition, and pre-existing neurological or medical conditions

modify how patients respond to therapy, thereby shaping their risk profiles. Older adults, for example, frequently exhibit heightened vulnerability to cognitive impairments due to age-associated structural brain changes and reduced metabolic resilience. Similarly, genetic variations in GABAergic pathways, the target of many AEDs, result in differing drug responses and side effect profiles across patient populations (Weimer, 2016, p. 2). These insights advocate for a personalized approach to AED therapy, where patient-specific factors are meticulously considered. Tailored pharmacogenomic testing may aid in predicting adverse cognitive outcomes, allowing clinicians to optimize treatment plans.

Valproic acid is widely utilized in epilepsy management due to its efficacy but is associated with severe neurotoxic effects, notably encephalopathy. This condition manifests as cognitive dysfunction, confusion, and lethargy, often caused by hyperammonemia, wherein elevated blood ammonia levels impair brain function (Hansen, Finzel & Block, 2010, p. 1). Approximately 20% of patients on valproic acid experience elevated ammonia levels, making routine biochemical monitoring a critical aspect of care. The neurotoxic effects are further exacerbated by valproic acid's modulation of the GABAergic system, leading to a compounding impact on cognitive and functional abilities (Weimer, 2016, p. 2). These risks are more pronounced in individuals with hepatic dysfunction or metabolic disorders, as these conditions hinder ammonia metabolism. Consequently, pre-treatment screening for liver function and ongoing monitoring during therapy are essential for reducing the likelihood of encephalopathy, particularly in high-risk groups.

Strategies to mitigate valproic acid-induced encephalopathy include co-administering adjunctive therapies like lactulose or l-carnitine. Lactulose reduces ammonia absorption from the gastrointestinal tract, while l-carnitine enhances mitochondrial metabolism, collectively alleviating hyperammonemia and its neurological effects. Such supportive interventions have demonstrated their utility in improving patient outcomes (Hansen, Finzel & Block, 2010, p. 1). Emerging research into biochemical markers may provide additional tools for early identification and management of hyperammonemia, offering a preventive framework for therapy adjustments. These advancements highlight the importance of integrating preemptive and adjunctive measures into treatment plans for patients prescribed valproic acid.

Second-generation AEDs, such as levetiracetam and lamotrigine, are associated with motor impairments like ataxia and balance disturbances. These adverse effects arise from disruptions to cerebellar circuits and synaptic transmission, critical for motor coordination. Such impairments elevate the fall risk in vulnerable populations, especially older adults and those on long-term therapy,

necessitating careful dose titration and monitoring (Hansen, Finzel & Block, 2010, p. 1). For levetiracetam specifically, its modulation of synaptic vesicle protein 2A (SV2A) underpins both its therapeutic efficacy and its motor side effects, illustrating the delicate balance between seizure management and safety (Kozłowski et al., 2015, p. 3). Reversible upon dosage adjustments or discontinuation, these effects underscore the importance of dynamic treatment strategies that adapt to patient responses.

The dose-dependent nature of ataxia and motor disturbances caused by AEDs demands a proactive clinical approach. Regular assessments of motor function and adjustments to therapy are imperative to minimizing long-term complications. Switching to alternative AEDs with lower neurotoxic potential or implementing physical rehabilitation programs may further mitigate the impact of motor impairments, particularly in patients with concurrent musculoskeletal vulnerabilities. These targeted interventions underscore the necessity of tailored care plans to reduce preventable risks tied to AED-induced motor dysfunctions.

Toxic neuropathies, which involve damage to sensory or motor nerves, represent another significant neurotoxic effect linked to AEDs like phenytoin and carbamazepine. Symptoms such as numbness, tingling, and chronic pain severely impair patients' quality of life, with the risk increasing proportionally to the cumulative drug dosage (Weimer, 2016, p. 1). Mitochondrial dysfunction and oxidative stress mechanisms, triggered by these medications, underlie the development of neuropathy. For instance, phenytoin disrupts calcium signaling and mitochondrial energy production, leading to progressive neuronal degradation over time. These findings highlight potential therapeutic avenues, such as incorporating antioxidants to mitigate oxidative damage, thereby reducing the long-term neurotoxic effects.

Management strategies for AED-induced neuropathy primarily focus on discontinuing the offending drug and symptomatic relief. Agents like gabapentin and pregabalin effectively manage neuropathic pain, while nutritional supplements, such as vitamin B12, may facilitate nerve repair and recovery (Pryadko et al., 2015, p. 47). Improved understanding of predictive biomarkers could further enhance early intervention strategies, enabling clinicians to identify at-risk patients and implement preventive measures. These multifaceted approaches ensure comprehensive management of AED-induced neuropathy, improving patient outcomes.

he increasing reliance on AEDs for off-label uses, alongside epilepsy management, has contributed to a rise in overdose cases reported to toxicological centers. Overdoses often result in severe CNS

effects, including sedation, respiratory depression, and coma, which necessitate vigilant dosage management (Hansen, Finzel and Block, 2010, p. 1). Older AEDs, such as phenobarbital, are particularly concerning due to their narrow therapeutic windows, increasing the likelihood of toxicological incidents. This underscores the importance of utilizing safer alternatives when possible and prioritizing patient education on adherence to prescribed regimens.

Polypharmacy involving AEDs and other CNS depressants significantly heightens the risk of overdose toxicity. This is especially true in elderly populations, where medication errors and interaction risks are more prevalent. Reducing polypharmacy through careful prescription choices and regular medication reviews is critical to decreasing the incidence of overdose-related complications. Preventive measures, such as improved accessibility to antidotes and enhanced patient counseling, further contribute to safer AED use in both clinical and community settings.

In conclusion, while AEDs are indispensable in epilepsy management, their associated neurotoxic effects demand careful consideration and proactive strategies to mitigate risks. Addressing cognitive impairments, motor disturbances, toxic neuropathies, and overdose risks requires an individualized, patient-centered approach to optimize therapeutic outcomes. Careful monitoring, personalized interventions, and ongoing research into the mechanisms of AED-induced neurotoxicity will be crucial in improving the safety and efficacy of these treatments.

9. Fluoroquinolones

Fluoroquinolones are a class of antibiotics widely used for their broad-spectrum activity, yet they are increasingly recognized for their considerable neurotoxic potential. The range of neurotoxic effects includes peripheral neuropathy, psychosis, and seizures, with evidence showing that 3.7% of veterans receiving fluoroquinolone treatment experienced psychosis or delirium (Anwar et al., 2024, p. 2). This significant percentage highlights the clinical relevance of these outcomes, particularly in older adults and individuals with pre-existing psychiatric conditions, who exhibit heightened susceptibility due to age-related changes in pharmacokinetics and pharmacodynamics. These observations underscore the importance of careful patient selection and monitoring during fluoroquinolone therapy, especially in these vulnerable populations.

The risk of peripheral neuropathy significantly increases with fluoroquinolone usage, rising by 3% for each additional day of treatment and persisting for as long as 180 days after discontinuation (Anwar et al., 2024, p. 2). Neuropathy symptoms, such as pain, numbness, and weakness,

considerably affect patients' quality of life and daily functioning. The prolonged duration of these symptoms highlights the chronic impact of fluoroquinolones on nerve health, necessitating stricter prescribing practices, particularly regarding treatment duration. This delayed onset of sustained neuropathy also indicates the need for extended patient follow-up to detect and address long-term complications.

Fluoroquinolones' neuropsychiatric side effects, such as psychosis, are thought to arise from disruptions in neurotransmitter systems or mitochondrial functioning within neurons (Weimer, 2016, p. 1). This reflects a complex interplay of biochemical and cellular mechanisms that require further investigation to fully elucidate. Such disruptions emphasize how fluoroquinolones affect not only peripheral systems but also wider CNS functions, suggesting a systemic pattern of neurotoxicity. Research into these mechanisms could guide strategies for mitigating these effects and even inform the redesign of safer antibiotic agents.

Fluoroquinolones significantly exacerbate pre-existing neurological conditions, such as myasthenia gravis, with symptoms such as muscle weakness developing rapidly, often within one day of exposure (Anwar et al., 2024, p. 2). These immediate effects highlight the potent and acute neurotoxic potential of fluoroquinolones, possibly through mechanisms that impair synaptic transmission or inhibit acetylcholine release (Weimer, 2016, p. 1). Given these risks, it is critical to evaluate a patient's medical history comprehensively before initiating fluoroquinolone therapy. For patients with aggravated neurological symptoms, discontinuing the medication promptly and exploring alternative therapies should be prioritized.

The susceptibility of specific populations, especially those with underlying conditions, underscores the need for personalized approaches in fluoroquinolone treatment. Genetic screening could potentially identify individuals at a higher risk of adverse effects, allowing for tailored therapeutic decisions. Personalized medicine approaches would enhance precautionary measures, reducing the occurrence of severe neurotoxic outcomes while maintaining therapeutic efficacy.

The neurotoxic mechanisms of fluoroquinolones are closely related to mitochondrial dysfunction, which results in oxidative stress and impaired energy metabolism in neurons. This damage manifests clinically as seizures, psychosis, and peripheral neuropathy, suggesting that the drugs induce widespread systemic effects on neuronal health (Was et al., 2022, p. 9; Anwar et al., 2024, p. 2). Mitochondrial health emerges as a focal point for understanding and addressing these neurotoxic effects. Interventions aimed at supporting mitochondrial function and mitigating oxidative stress

could serve as protective strategies against these adverse consequences.

Oxidative stress plays a pivotal role in the neurotoxic profile of fluoroquinolones, as evidenced by increased free radical production and reduced antioxidant defenses following drug exposure (Weimer, 2016, p. 1). This imbalance leads to neuronal damage, further contributing to the long-term neurological impairments frequently observed among patients. Antioxidant-based therapies could be explored to counter this mechanism, offering a potential avenue for reducing the severity and duration of neurotoxic effects associated with fluoroquinolone use.

Fluoroquinolones also interfere with ion channel activity in neuronal cells, disrupting electrical signaling and leading to acute neurological events such as seizures (Anwar et al., 2024, p. 2). This pharmacological property amplifies their neurotoxic potential and underscores the necessity for detailed mechanistic studies to identify safer modifications to their molecular structure. Understanding these interactions at a molecular level could inform the development of antibiotics with reduced neurotoxicity while preserving their antimicrobial efficacy.

The prevalence of adverse drug reactions among fluoroquinolone users is notably higher than in non-fluoroquinolone antibiotic users, with 8.5% of patients experiencing adverse reactions compared to 4.1% (Anwar et al., 2024, p. 5). This marked disparity highlights the need for stricter prescribing guidelines and a heightened awareness of the risks associated with fluoroquinolones. Their ability to cross the BBB exacerbates their neurotoxicity compared to antibiotics that do not as readily interact with CNS structures (Weimer, 2016, p. 1). These findings further stress the necessity of conducting thorough risk-benefit analyses before prescribing fluoroquinolones, particularly in populations predisposed to adverse neurological outcomes.

The long-term consequences of fluoroquinolone-induced neurotoxicity, such as persistent neuropathy and elevated risks of psychosis or delirium, profoundly impair patients' overall quality of life. These enduring effects necessitate comprehensive post-treatment care strategies, including neurological and psychological monitoring for months beyond treatment cessation (Anwar et al., 2024, p. 2). The prolonged nature of symptoms also suggests that some forms of nerve damage may become irreversible, emphasizing the urgency of early symptom detection and timely medical intervention (Weimer, 2016, p. 1). Revising clinical guidelines to recommend shorter treatment durations and highlighting alternative antibiotic options could significantly reduce the burden of these side effects.

The challenges posed by fluoroquinolones reveal substantial gaps in current clinical practice,

particularly in post-marketing surveillance, where rare but severe side effects often go underreported. Enhanced surveillance measures could provide critical insights into the full scope of neurotoxic risks, aiding in the development of targeted mitigation strategies. Research into therapeutic interventions to reverse fluoroquinolone-induced damage also remains an urgent need, particularly concerning mechanisms to promote neurological recovery post-exposure.

While evidence on fluoroquinolones' mitochondrial and oxidative effects primarily focuses on their neuronal impairment, their broader systemic impact shares similarities with well-known drug toxicities in other contexts, such as those observed with chemotherapy agents and their effects on peripheral nerves. Chemotherapy-induced toxicities, including bone marrow suppression and peripheral cytopenia, are significant clinical challenges due to their dose-limiting nature and potential progression to life-threatening conditions such as severe infections or hemorrhage (Remesh, 2012, p. 2). The hematopoietic damage caused by these agents emphasizes the systemic repercussions of drugs with high oxidative stress potential, common to both chemotherapy and fluoroquinolone therapies.

Additionally, the oxidative stress mechanisms of fluoroquinolones align with pathways implicated in cardiotoxic drugs, as identified by Iqubal et al. (2018, p. 2). Cardiotoxicity resulting from drugs like anthracyclines is primarily mediated by oxidative stress, free radical generation, and cellular hypoxia. Fluoroquinolones, through similar mitochondrial disruptions, may exhibit compounded effects in patients with predisposing conditions such as cardiac vulnerabilities. This comparison emphasizes the significance of oxidative pathways in drug-induced systemic toxicities, further supporting the argument for antioxidant-based interventions across drug classes.

In conclusion, fluoroquinolones present a complex neurotoxic profile that demands cautious clinical application and further research to address both acute and long-term effects. Enhanced prescribing practices and patient education are essential in mitigating the risks while optimizing therapeutic benefits.

10. Cancer Treatments

The intersection of cancer treatments and neurotoxicity presents a critical domain within pharmacological research, revealing the complexities of balancing therapeutic efficacy against significant neurological risks. The ensuing sections will explore the neurotoxic effects associated with various chemotherapy agents, emphasizing the mechanisms of action that lead to adverse outcomes such as peripheral neuropathy and cognitive impairments. By examining these effects, patient-

specific factors, and potential mitigation strategies, this discussion aims to illuminate the urgent need for personalized approaches to optimize cancer care while safeguarding neurological health.

10.1 Chemotherapy Agents

Chemotherapy agents are among the most effective treatments in oncology; however, they are notoriously associated with significant neurotoxic side effects. One of the most concerning agents in this regard is bortezomib, known for inducing apoptosis in neuronal cells through its inhibition of the 26S proteasome. By disrupting proteasome function, bortezomib causes the accumulation of misfolded or damaged proteins, increasing cellular stress and ultimately leading to neuronal apoptosis (Bashir, Aziz & Noor, 2021, p. 2). This mechanism underlies the high prevalence of neuropathic symptoms in bortezomib-treated lymphoma patients, with 84.4% experiencing severe sensory neuropathy. This neuropathy not only disrupts sensory functions but detracts from patients' overall quality of life, emphasizing the pressing need for mitigative approaches such as dose adjustments or the development of neuroprotective adjunctive therapies.

The neurotoxic effects of bortezomib are closely linked to oxidative stress and the generation of ROS, which overwhelm the brain's antioxidant defenses. These processes are confirmed by in vitro models, such as neuronal apoptosis observed in PC12 cells, which illustrate the neurodegenerative pathways activated by bortezomib (Bashir, Aziz & Noor, 2021, p. 2). ROS accumulation triggers further mitochondrial dysfunction and cellular damage, illustrating the cascading effects of oxidative stress on neuronal survival. Given these insights, exploring antioxidant therapies as potential protective measures could offer significant benefits, such as reducing oxidative damage and improving patients' tolerance to bortezomib therapy. Future research should focus on antioxidant agents that can target these molecular pathways without impeding the drug's anticancer efficacy.

The clinical manifestation of bortezomib-induced peripheral neuropathy typically includes burning sensations, numbness, and tingling in the extremities. These symptoms can have debilitating implications for patients, severely restricting mobility and independence. Neuropathy-related limitations also impact therapeutic adherence, as patients may require reductions in dosage or early discontinuation of treatment, potentially compromising oncological outcomes. Identifying early biomarkers for neuropathy could enable healthcare practitioners to adjust doses preemptively or initiate nerve-protective strategies, ultimately improving the therapeutic experience for patients undergoing chemotherapy.

Platinum-based chemotherapy agents, such as cisplatin and oxaliplatin, are equally notorious for their

neurotoxic implications. Cisplatin demonstrates a high incidence of sensory and sensorimotor neuropathy, affecting 50%-85% of treated patients (Bashir, Aziz & Noor, 2021, p. 2). The underlying mechanism involves platinum moieties binding to guanosine and adenosine in DNA, leading to the formation of crosslinks that inhibit replication and transcription. This inhibition arrests the neuronal cell cycle, further promoting apoptosis (Was et al., 2022, p. 4). While these molecular interactions are crucial to the agents' cytotoxic efficacy in killing tumor cells, they have far-reaching toxic consequences for neuronal integrity. Developing strategies that target tumor cells while sparing neurons remains one of the most critical challenges in reducing the adverse effects of platinum-based therapies.

The sensory neuropathy induced by cisplatin is striking in its persistence, with symptoms such as pain and numbness often lingering long after treatment cessation. In fact, cisplatin has been detected in the body up to 20 years post-administration, signifying its long-term retention and ongoing cytotoxic effects on the nervous system (Myers, Pierce & Pazdernik, 2008, p. 2). This protracted elimination underscores the necessity for extended post-treatment monitoring and the development of interventions to alleviate chronic neuropathy. Furthermore, long-term studies could help elucidate how cisplatin's retention in the body correlates with progressive neurological decline, providing a foundation for more targeted therapeutic strategies.

Oxaliplatin, although sharing similarities with cisplatin, has its own distinct neurotoxic profile. Its acute neurotoxicity manifests as unique symptoms, including muscle cramps, paresthesia, and heightened cold sensitivity. These symptoms are attributed to the acidification of dorsal root ganglia neurons, a mechanism distinct from cisplatin’s DNA crosslinking effects (Was et al., 2022, p. 6). The exacerbation of symptoms by cold exposure further complicates treatment regimens, requiring thermal precautions to mitigate discomfort. Developing interventions that neutralize dorsal root ganglia acidification could serve as a novel approach to managing oxaliplatin-induced neuropathies without disrupting its efficacy.

The neurotoxic implications of chemotherapy agents extend beyond peripheral symptoms, encompassing cognitive impairments colloquially termed "chemo brain." This phenomenon, which affects 17%-75% of patients during and after adjuvant chemotherapy, is characterized by memory deficits, diminished attention, and reduced executive function (Myers, Pierce and Pazdernik, 2008, p. 1). Cognitive dysfunction poses significant challenges for cancer survivors, impacting their ability to reintegrate into professional and social environments. The variability in reported prevalence suggests that individual susceptibility, including genetic predispositions and baseline cognitive reserve, plays

a critical role in determining the severity of cognitive impairments. This variability underscores the need for personalized treatment strategies to minimize cognitive side effects while maintaining therapeutic benefits.

Mechanistically, cytokine-mediated neuroinflammation and (BBB) dysfunction have been implicated in chemotherapy-induced cognitive impairments. Chemotherapeutic agents like cisplatin can cross or compromise the BBB, leading to elevated drug concentrations in the CNS and subsequent neurological damage (Myers, Pierce and Pazdernik, 2008, p. 1). This disruption not only facilitates direct neurotoxicity but also amplifies inflammatory responses within the brain, exacerbating cognitive decline. These findings emphasize the importance of exploring neuroprotective agents that can reinforce the integrity of the BBB or modulate inflammation during chemotherapy.

MTX, widely employed in the treatment of childhood acute lymphoblastic leukemia (ALL), presents its own neurotoxic risks, with reported incidence rates of 3%-11% (Shuper et al., 2002, p. 1). Clinical manifestations of MTX neurotoxicity include acute seizures and occlusive vascular-like events. Pathological findings reveal diffuse necrotizing lesions, demyelination, reactive astrocytosis, and calcium deposition, underscoring the agent's potential to inflict widespread neuronal damage (Shuper et al., 2002, p. 1). These neurotoxic effects pose a particular challenge in pediatric oncology, where the developing brain is more vulnerable to structural and functional impairments. Optimizing MTX dosing to balance its therapeutic efficacy with its neurotoxic risks is essential in improving long-term outcomes for pediatric patients.

Elevated homocysteine levels during MTX therapy have been linked to endothelial cell injury and cerebral infarctions, further highlighting its neurotoxic impact (Shuper et al., 2002, p. 2). Addressing this biochemical mechanism through concurrent folate supplementation or personalized dosing protocols could significantly reduce the incidence of vascular-related neurotoxicity. Exploring these targeted mitigation strategies is crucial in limiting the neurological burden associated with MTX.

Long-term survivors of childhood ALL who undergo chemotherapy demonstrate varying degrees of neuropsychological sequelae. Research indicates that 14% of these survivors experience moderate impairments, and 3% show severe somatic or neuropsychological consequences (von der Weid, 2001, p. 1). Importantly, chemotherapy-only treated patients display significantly better cognitive outcomes, as reflected in global and verbal IQ scores, compared to those who also received cranial irradiation. This suggests that avoiding cranial irradiation when feasible could reduce the neurotoxic impact of ALL treatment. However, even in chemotherapy-only groups, subtle deficits in non-verbal

IQ and specific cognitive domains persist, underscoring the need for longitudinal assessments and rehabilitative interventions to address these challenges.

Irradiated children, in particular, fare poorly in measures of short-term verbal memory, arithmetic performance, and processing speed, as assessed by the Wechsler scale (von der Weid, 2001, p. 1). These deficits can impede academic and social development, underlining the necessity for tailored educational support and cognitive rehabilitation programs. Further investigations into the mechanisms underlying these specific impairments, including radiation-induced neuronal damage, could aid in refining treatment protocols to mitigate these long-term consequences.

Endocrine dysfunction is another critical concern in survivors of childhood ALL, with 14% of children presenting with such issues, including gonadal dysfunctions in some cases (von der Weid, 2001, p. 3). This highlights the systemic implications of chemotherapy, necessitating multidisciplinary care approaches that address both neuropsychological and physiological sequelae. These findings stress the importance of routine endocrine evaluations and early interventions to improve the overall quality of life for long-term survivors.

Chemotherapy-induced peripheral neuropathy (CIPN) stands out as a chronic issue for many cancer survivors, persisting in 30% of patients even five months post-treatment (Was et al., 2022, p. 2). The symptoms of CIPN, such as tingling and neuromuscular weakness, frequently require patients to depend on assistance for daily activities, thereby diminishing their independence and overall quality of life (Jing, Lv and Feng, 2016, p. 3). Given its chronicity, addressing CIPN necessitates a combination of early detection measures, rehabilitative strategies, and therapeutic interventions aimed at nerve repair and symptom management.

The underlying mechanisms of CIPN, including mitochondrial dysfunction and ROS generation, further reinforce the role of oxidative stress in chemotherapy-induced neurotoxicity. Paclitaxel, in particular, destabilizes microtubules by promoting their polymerization, thereby interfering with mitotic spindle formation and contributing to apoptosis within peripheral nerves (Was et al., 2022, p. 7). Understanding these molecular processes has the potential to inform the development of pharmacological agents that specifically target and mitigate these effects without compromising the therapeutic benefits of chemotherapy.

The persistence of CIPN symptoms underscores the need for long-term supportive care tailored to the needs of cancer survivors. For instance, integrating adjunctive neuroprotective agents during

treatment or implementing rehabilitative programs post-treatment could significantly enhance patient quality of life. The chronic nature of these symptoms also highlights the importance of incorporating long-term follow-up into oncology care plans to address patients' ongoing neurological needs and promote functional recovery.

Collectively, the neurotoxic effects of chemotherapy represent a significant challenge in oncology, necessitating a comprehensive, multi-faceted approach to treatment. From peripheral neuropathy to cognitive impairments to systemic effects, these adverse outcomes demand targeted interventions, ongoing research, and personalized strategies to optimize patient outcomes while minimizing long-term harm.

10.2 Impact on Cognitive Function

Chemotherapy-induced cognitive impairment (CICI), often referred to as "chemo brain," represents a significant concern for cancer patients and survivors, with prevalence estimates ranging from 17% to 75% shortly after the completion of adjuvant treatment. Persisting as long-term deficits in 17%-35% of cases, the condition underscores a substantial burden on patients' cognitive and overall quality of life (Myers, Pierce & Pazdernik, 2008, p. 1). This variability in prevalence highlights the need for standardized research methodologies and diagnostic criteria to better understand the true scope of CICI. Factors such as diverse patient populations, inconsistent assessment tools, and variations in chemotherapy regimens likely contribute to these discrepancies, complicating efforts to systematically address the issue. The cognitive challenges posed by CICI affect patients' ability to perform daily tasks, reinforcing the necessity for targeted interventions that consider its pervasive and enduring impact.

The array of CICI symptoms includes memory lapses, difficulty concentrating, and executive dysfunction, which collectively hinder patients' autonomy and quality of life. These impairments limit their ability to reintegrate into professional and social environments, creating additional psychological and emotional stress. Individuals undergoing combination chemotherapy regimens appear to exhibit more pronounced symptoms, likely reflecting a cumulative neurotoxic burden from exposure to multiple agents. This observed association warrants further investigation to identify specific drugs or combinations that disproportionately contribute to cognitive impairments. The persistence of these deficits, even years after treatment cessation, highlights the necessity of long-term follow-up care and the exploration of interventions such as cognitive training programs and pharmacological treatments aimed at neuroprotection, neuroinflammation reduction, and oxidative

stress mitigation.

The severity of CICI demonstrates significant variability, as illustrated by reports that approximately 50% of women undergoing chemotherapy for breast cancer experience mild to moderate deficits, often characterized as subtle and challenging to detect (Staat and Segatore, 2005, p. 1). A small minority of cases, however, experience symptoms that persist for up to 10 years, profoundly affecting long-term quality of life. Current diagnostic tools may lack the sensitivity to identify these subtle deficits, underscoring the need for more advanced screening techniques that can detect even mild impairments. Variations in symptom severity are influenced by a multitude of factors, including cancer type, patient age, pre-existing comorbidities, and genetic predispositions. These observations suggest that the manifestation of CICI is not uniform and instead represents a complex interplay of individual and therapeutic factors. For survivors facing persistent deficits, tailored support systems and recovery programs should be prioritized to facilitate their reintegration into society and the workforce. Gender-specific differences, particularly in breast cancer patients, further point to potential hormonal or treatment-related factors that amplify cognitive risks, underscoring the importance of conducting gender-targeted studies to refine treatment approaches.

Cytokine release and BBB disruption have emerged as central mechanisms underpinning chemotherapy-induced neurotoxicity. Elevated cytokine levels, particularly interleukins (IL-1 and IL-6) and tumor necrosis factor-alpha, adversely influence neuronal functioning and exacerbate neuroinflammation (Myers, Pierce & Pazdernik, 2008, pp. 1-2). Disruption of the BBB by chemotherapy agents permits higher-than-expected concentrations of these drugs in the brain and cerebral spinal fluid, further amplifying damage to critical neurological pathways. These dual processes contribute to chronic neurodegeneration, compounding the cognitive challenges faced by patients. Animal studies have confirmed that BBB compromise accelerates neural exposure to cytotoxic agents, offering insights into the biological basis of CICI. Cytokine overproduction has been shown to impair hippocampal neurogenesis and synaptic plasticity, processes integral to memory formation and spatial awareness. These findings underscore the importance of developing therapies to maintain BBB integrity and manage cytokine levels, such as targeted anti-inflammatory agents or cytokine inhibitors, which hold potential as adjunct treatments for chemotherapy-induced cognitive decline.

Certain subpopulations, such as triple-negative breast cancer (TNBC) patients and younger individuals, face a heightened risk of chemotherapy-induced cognitive impairments. Younger patients often receive more aggressive treatment regimens, which may exacerbate neurotoxic effects

compared to older patients undergoing less intensive protocols (Liu et al., 2018, pp. 1-2). The more severe deficits observed in younger TNBC patients may also reflect differences in baseline cognitive reserve, which influences resilience to neurotoxic insults. Additionally, genetic markers associated with TNBC, such as BRCA1 mutations, might predispose these patients to greater susceptibility to cognitive impairments, further highlighting the importance of personalized therapeutic strategies. Hormonal shifts in premenopausal TNBC patients undergoing chemotherapy may compound neurotoxic effects, emphasizing the need for research into potential protective hormonal interventions. Tailored neurorehabilitation programs that focus on memory enhancement and executive function restoration could address the specific cognitive challenges faced by these patients, improving their quality of life and overall recovery outcomes.

Structural and functional brain changes caused by chemotherapy further illustrate its neurotoxic impact. MTX, for example, has been linked to necrotizing lesions, astrocytic activation, and elevated homocysteine levels, which collectively contribute to endothelial injury and cognitive impairments (Bashir, Aziz & Noor, 2021, p. 2). Demyelination and white matter damage undermine neural communication across the brain, disrupting higher-order cognitive processes such as attention, memory, and information processing speed. Neuroinflammation, often induced by high-dose chemotherapy regimens, exacerbates these effects and creates a feedback loop of progressive cognitive decline. Elevated homocysteine levels impair cerebral blood flow and neuronal energy metabolism, compounding the cognitive challenges faced by survivors. Advances in neuroimaging have revealed structural alterations in key brain regions, such as the prefrontal cortex and hippocampus, providing further evidence of chemotherapy-induced brain damage. These findings highlight the need for optimized treatment protocols, including the use of functional imaging to monitor neurotoxicity and guide personalized therapeutic adjustments.

Delirium is another prevalent and multifactorial complication of chemotherapy, particularly in advanced cancer patients. Hyperactive subtypes of delirium manifest through symptoms such as restlessness, hallucinations, and hypervigilance, resembling psychotic or manic states (El Majzoub et al., 2019, p. 1). Its development is often driven by disruptions in neurotransmitter pathways, such as dopamine and acetylcholine systems, and is further exacerbated by metabolic disturbances, infections, and systemic inflammation. Cancer patients undergoing immunosuppressive treatments are particularly vulnerable to infections, which amplify the inflammatory and neurochemical disruptions underlying delirium. Metabolic derangements, including hypercalcemia and hypoglycemia, also contribute significantly to delirium risk by further destabilizing neuronal homeostasis. This condition is especially common in palliative care settings, where prevalence

increases dramatically toward the end of life. Early risk assessments and intervention strategies are crucial in reducing the severity and incidence of delirium. Non-pharmacological management techniques, such as environmental modifications and reorientation strategies, present promising approaches to addressing delirium without exacerbating its neurotoxic effects.

In summary, the cognitive impairments associated with chemotherapy are multifaceted and demand a comprehensive approach to prevention, intervention, and management. These effects, ranging from memory deficits to delirium, underscore the need for further research and personalized therapeutic strategies to improve patient outcomes while mitigating long-term neurotoxic consequences.

10.3 Long-term Neurological Effects

Chemotherapy-induced peripheral neuropathy (CIPN) represents a severe and enduring complication of cancer treatment that significantly compromises patients' quality of life. The condition is marked by symptoms such as tingling sensations, burning pain, numbness, or muscle weakness, which frequently persist months or even years after the cessation of chemotherapy. Approximately 30% of patients report CIPN symptoms five months after completing treatment, highlighting its chronic nature (Was et al., 2022, p. 2). These impairments in neuromuscular coordination often result in profound functional limitations, such as difficulties with balance and daily tasks, which substantially diminish patients' independence and life satisfaction. With nearly half of CIPN-affected individuals requiring external assistance for routine activities, the socio-economic and emotional impact of this condition is evident (Jing, Lv & Feng, 2016, p. 3). Among patients treated with chemotherapeutic agents like bortezomib, a staggering 84.4% develop serious neuropathy affecting sensory organs, emphasizing the extensive prevalence and severity of these complications (Bashir, Aziz & Noor, 2021, p. 1). This underlines an urgent need for therapeutic strategies, such as neuroprotective medications and physical therapy, to address the debilitating effects of CIPN and help preserve patients' autonomy.

The persistent nature of CIPN reflects a complex pathophysiology driven by various mechanisms. Chemotherapy agents, such as paclitaxel, destabilize microtubules and disrupt mitochondria, ultimately inducing apoptosis in peripheral neurons (Was et al., 2022, p. 7). Sensory and motor nerve fibers are particularly vulnerable, with agents such as platinum compounds exacerbating damage through intracellular oxidative stress (Bashir, Aziz & Noor, 2021, p. 2). Cisplatin, for instance, induces neuropathy in 50%-85% of treated patients, causing symptoms that range from sensory to sensorimotor impairments (Bashir, Aziz & Noor, 2021, p. 2). The cumulative damage from these

mechanisms underscores the importance of advancing research into potential neuroprotective agents capable of mitigating neuronal injury without compromising the efficacy of chemotherapy. Although some studies have explored the modulation of oxidative pathways as a therapeutic approach, the challenge lies in effectively targeting these pathways to prevent nerve damage while preserving the primary cancer-fighting properties of the treatment.

Cognitive impairments associated with chemotherapy are equally concerning, as they prevent survivors from fully regaining their cognitive function post-treatment. Often referred to as "chemo brain," these deficits include difficulties with memory, attention, and executive functioning, and they may persist for years, with some cases enduring up to a decade after chemotherapy (Staat & Segatore, 2005, p. 1). Cisplatin, in particular, has been noted for its extended neurotoxic influence, remaining detectable in the body for up to 20 years post-treatment (Myers, Pierce and Pazdernik, 2008, p. 2). Current estimates suggest that between 17% and 35% of survivors experience long-term cognitive effects (Myers, Pierce & Pazdernik, 2008, p. 1). Approximately 50% of women undergoing chemotherapy for breast cancer report cognitive dysfunctions, with symptoms varying in severity from mild to moderate (Staat & Segatore, 2005, p. 1). These persistent effects highlight the need for improved monitoring and targeted interventions, such as cognitive rehabilitation therapies, to alleviate long-term damage and enhance the quality of life for survivors. Furthermore, the variability in response among patients suggests the potential for interventions tailored to individual vulnerabilities, possibly identified through genetic or molecular markers.

The mechanisms underlying cognitive impairments are multifaceted, involving both structural and functional changes in the brain. Chemotherapy agents such as MTX are known to elevate homocysteine levels, which disrupt the BBB and cause endothelial injury, leading to cognitive impairments (Bashir, Aziz & Noor, 2021, p. 2). Elevated cytokine levels during chemotherapy further exacerbate neuronal dysfunction and cognitive decline, as many agents cross or compromise the BBB, resulting in higher-than-expected concentrations in the CNS (Myers, Pierce & Pazdernik, 2008, pp. 1-2). The ensuing neuroinflammation and disruption of neural networks disrupt memory, attention, and other higher-order cognitive functions. These findings emphasize the importance of interventions aimed at preserving BBB integrity and managing inflammatory cytokines, such as the use of targeted anti-inflammatory therapies. Although promising, these strategies require further clinical studies to determine their efficacy and safety alongside standard chemotherapeutic protocols.

Evidence from studies into SSRIs highlights how drug-induced neurotoxic effects can extend to hippocampal plasticity and memory function, mechanisms that might also play a critical role in

understanding chemotherapy-induced impairments. Fluvoxamine, for instance, has been shown to overcome LTP inhibition when applied in pro-inflammatory conditions such as those induced by lipopolysaccharides (LPS) (Izumi et al., 2023, p. 3). Similarly, fluoxetine at specific concentrations (3 μM) can fully mitigate the LTP inhibition caused by LPS, demonstrating its potential protective effects on synaptic plasticity (Izumi et al., 2023, p. 4). However, sertraline at comparable levels exhibited an inhibitory effect on LTP when administered alone, highlighting the diversity in neurotoxic potential among SSRIs (Izumi et al., 2023, p. 4). These findings are instrumental in drawing parallels to chemotherapy-induced neural damage, as they establish a precedent for exploring the duality of pharmacological agents. By investigating specific molecular interactions and optimizing dosing regimens, it may be possible to identify adjunctive therapies capable of mitigating the adverse neurocognitive outcomes linked to chemotherapy.

Calcineurin inhibitors, such as tacrolimus, introduce an additional layer of long-term neurotoxic risks, especially in cancer-related procedures like organ transplants. These agents are associated with neurological complications, including cognitive impairments and mild tremulousness, particularly in the hippocampus and cerebral cortex (Zhang et al., 2022, p. 7). Tacrolimus induces mitochondrial dysfunction and impairs the BBB by promoting apoptosis and nitric oxide production (Zhang et al., 2022, pp. 2-3). Such disruptions contribute to subtle yet chronic cognitive declines in transplant recipients, raising the necessity for routine neurological evaluations and the potential exploration of alternative immunosuppressive strategies. While calcineurin inhibitors are critical in suppressing immune responses post-transplant, understanding their neurotoxic mechanisms can guide the development of adjunct therapies that mitigate these adverse effects without compromising their therapeutic utility.

The long-term neurological effects of chemotherapy are exacerbated by factors such as younger age, genetic predispositions, and specific cancer subtypes like TNBC. Research reveals that younger breast cancer patients treated with chemotherapy experience greater cognitive deficits, as measured by tests like the mini-mental state examination(MMSE) and assessments of memory and recognition, compared to older patients and healthy controls (Liu et al., 2018, pp. 1-2). Up to 77% of premenopausal women undergoing chemotherapy suffer from ovarian failure, compounding their vulnerability to cognitive impairments (Staat & Segatore, 2005, p. 2). The heightened susceptibility to neurotoxic damage in these demographics underscores the necessity of risk-adapted strategies, such as integrating neurogenetic screening and personalized therapeutic interventions, to optimize treatment outcomes while minimizing long-term cognitive damage. Moreover, the interplay of hormonal changes with chemotherapy-induced cognitive deficits highlights an area that necessitates

further investigation into potential protective hormonal interventions.

Cardiovascular alterations induced by chemotherapy also contribute to long-term neurotoxic risks. Studies on patients with polycythemia vera (PV) demonstrate decreased sympathetic nervous system activity, including lower norepinephrine secretion and reduced blood pressure variability, both of which impact neurological resilience over time (Jóźwik-Plebanek et al., 2020, pp. 607-609). Dysregulation of autonomic function has been linked to a greater risk of neurodegenerative conditions such as dementia and cognitive decline. These findings emphasize the importance of cardiovascular monitoring in cancer patients undergoing chemotherapy, as strategies aimed at improving cardiovascular health could mitigate compounded neurological risks. However, a deeper exploration of the mechanisms connecting cardiovascular changes and neurological outcomes is necessary to develop more integrative management approaches.

In conclusion, the long-term neurological consequences of chemotherapy involve a combination of peripheral and central mechanisms that significantly affect survivors' quality of life. From CIPN to cognitive impairments and cardiovascular-induced neurotoxicity, these challenges point to the need for advancements in research, targeted interventions, and comprehensive follow-up care strategies to mitigate neurotoxic damage while optimizing therapeutic outcomes.

11. Results and Discussion

This literature review identified consistent patterns of neurotoxicity across several classes of medications. The findings support the idea that commonly prescribed medications can impair the integrity of our nervous systems through overlapping biological mechanisms, with severity varying depending on the medication class, dosage, patient-specific factors, and duration of treatment.

Across all medication categories studied – cardiovascular medications, gastrointestinal and anti-inflammatory medications, psychiatric medications, fluoroquinolones, and chemotherapy agents – cognitive impairment emerged as a recurrent neurotoxic manifestation. These effects can be mild, ranging from mild memory loss and confusion (statins, PPIs) to severe and often irreversible cognitive deficits in patients undergoing chemotherapy. Chemotherapy-induced cognitive impairment, commonly referred to as "chemobrain," has been one of the best characterized outcomes, with strong evidence linking it to oxidative stress, neuroinflammation, and disruption of the BBB.

Multiple classes, including statins, SSRIs, AEDs, and chemotherapeutic agents, were consistently linked to mitochondrial dysfunction as a core neurotoxic mechanism. This was usually accompanied by elevated oxidative stress, leading to apoptosis and impaired synaptic function. In the case of SSRIs, cognitive and mood disturbances were attributed to disruptions in neuroplasticity and LTP in the hippocampus. The paradoxical nature of such medications – providing therapeutic psychiatric benefit while posing long-term cognitive risks – demonstrates the delicate balance clinicians must navigate in managing chronic conditions.

Neuroinflammation was another major common mechanism across multiple drug classes, implicating chemotherapy agents like DXR and cisplatin, NSAIDs, and PPIs. These inflammatory processes contributed not only to direct neuronal injury but also to secondary effects such as altered signalling and reduced neurogenesis. Emerging evidence also pointed to gut-brain axis dysfunction as a novel pathway of neurotoxicity, particularly in gastrointestinal medications like PPIs and NSAIDs. These drugs alter gut microbiota composition, which in turn influences neuroinflammation and mood.

While peripheral neuropathy was less universally observed, it was prevalent in three drug categories: AEDs, fluoroquinolones, and chemotherapy agents. Cisplatin and taxanes caused long-lasting neuropathies via axonal degeneration and mitochondrial damage. Fluoroquinolones disrupted ion channels and neuromuscular signaling, leading to acute neuropathic symptoms. Phenytoin and Carbamezapine caused neuropathies through mitochondrial dysfunction and oxidative stress. These findings underscore the need for routine neurological monitoring in patients prescribed these agents, particularly during long-term therapy.

Importantly, some medications exerted mood disturbances or behavioral side effects, independent of cognitive deficits. Beta-blockers, for example, were associated with fatigue, depressive symptoms, and in some cases, postoperative delirium. Lipophilic beta-blockers that cross the BBB had more pronounced central effects, whereas hydrophilic counterparts appeared safer. Antihistamines, particularly first-generation agents, also caused sedation and attentional impairment, effects that were dose-dependent and pronounced in older adults or in contexts of polypharmacy.

From a clinical perspective, the results support a growing consensus that age, genetic polymorphisms, and comorbidities greatly modify neurotoxic risk. Polymorphisms in cytochrome P450 enzymes and P-glycoprotein transporters influenced drug metabolism and CNS exposure, while renal impairment was shown to exacerbate neurotoxic effects of drugs like baclofen and statins. Elderly patients,

already prone to cognitive decline, were particularly susceptible due to age-related changes in drug clearance and BBB permeability.

This review also identified a critical gap in the literature regarding longitudinal human studies. While animal models and in vitro experiments have clarified mechanisms like mitochondrial toxicity and neurotransmitter dysregulation, clinical studies often lack the power or specificity to establish causality. Additionally, most studies focus on individual drugs or conditions, making it difficult to generalize. There is a need for large-scale cohort studies and pharmacovigilance systems that incorporate genetic screening, environmental exposures, and polypharmacy profiles.

The strengths of this review lies in its broad scope and evaluation of multiple mechanisms. By synthesizing data from different drug classes and mechanisms, it offers clinicians an understanding of neurotoxic risks that might otherwise be overlooked in drug monographs or standard practice. The inclusion of multiple evidence types, ranging from clinical trials and observational data to mechanistic studies, enhances the depth and applicability of the findings. However, as a narrative review, this study lacks a quantitative meta-analysis or statistical synthesis. The reliance on published literature introduces publication bias, and the interpretation of causality is restricted by variability in study design, sample size, and outcome measures. Furthermore, while efforts were made to include the most recent and clinically relevant studies, rapid developments in pharmacogenomics and neuroimaging may soon outdate some conclusions.

In summary, this review highlights a need for more proactive recognition of drug-induced neurotoxicity in clinical settings. Cognitive and neurological effects are not confined to niche or high-dose treatments; they can emerge from the everyday medications used in cardiology, psychiatry, gastroenterology, and oncology. With the integration of personalized medicine approaches(e.g. pharmacogenetic screening, patient-specific dosing, improved clinician education), neurotoxic risks can be minimized without compromising therapeutic efficacy. Continued research and vigilance are essential to support safer, more neurologically-informed prescribing practices.

12. Conclusion

The primary objective of this work was to investigate and elucidate the neurotoxic effects of commonly prescribed medications, aiming to provide a comprehensive understanding of their mechanisms, risk factors, and clinical consequences. By exploring the interplay between pharmacological action and neurotoxicity across various drug classes, the study sought to enhance

awareness of this underexplored aspect of modern pharmacotherapy. The findings of this research successfully address this goal, demonstrating a robust analysis of neurotoxic pathways, patient-specific vulnerabilities, and the implications for healthcare practices.

The main part of this study systematically detailed the mechanisms of neurotoxicity, ranging from oxidative stress and mitochondrial dysfunction to neurotransmitter dysregulation, neuroinflammation, ion channel interference, and BBB disruption. These mechanisms were shown to operate across a wide diversity of medication classes, each with its own distinct neurotoxic profile. Central to this exploration was the demonstration that oxidative stress and mitochondrial dysfunction form a common thread linking neurotoxic effects across drug categories, with chemotherapeutic agents, SSRIs, beta-blockers, PPIs, and fluoroquinolones consistently disrupting neuronal integrity through these processes. Additionally, the clinical manifestations of these neurotoxic pathways span a spectrum of acute symptoms, such as seizures and encephalopathy, to chronic conditions, including cognitive decline, neuropathy, and neuropsychiatric disturbances. By incorporating recent advancements in mechanistic research, the study underscored the central role of neuroinflammatory cascades in exacerbating cognitive and functional impairments, particularly in patients experiencing prolonged or high-dose drug exposure.

A critical dimension of this work focused on patient-specific factors that modulate the risk of neurotoxic outcomes. Genetic predispositions, such as polymorphisms in the CYP450 enzyme family or transport proteins like P-glycoprotein, were highlighted as key contributors to interindividual variability in drug metabolism and susceptibility to neurotoxic effects. Furthermore, comorbid conditions, such as chronic kidney disease or pre-existing neurological disorders, were shown to amplify neurotoxicity by impairing drug clearance or aggravating underlying vulnerabilities. Age emerged as a particularly significant factor, with older adults demonstrating heightened susceptibility to neurotoxic effects due to reduced metabolic capacity, increased BBB permeability, and polypharmacy. Collectively, these patient-specific variables emphasized the critical importance of personalized medicine in mitigating neurotoxic risks.

Across the various drug classes analyzed, specific neurotoxic profiles were identified, shedding light on their distinct mechanisms and implications. Cardiovascular drugs, such as statins and beta-blockers, were shown to affect cognitive function and induce neuropsychiatric symptoms through mitochondrial dysfunction and neurotransmitter imbalances. Gastrointestinal agents, particularly PPIs, emerged as underrecognized contributors to cognitive decline, with mechanisms involving vitamin B12 deficiency, hypomagnesemia, and gut-brain axis disruptions. Psychiatric and

neurological medications, such as SSRIs and AEDs, were demonstrated to impact memory, motor coordination, and synaptic plasticity, with the potential for severe conditions like serotonin syndrome or hyperammonemic encephalopathy. Fluoroquinolones, despite their utility as antibiotics, were linked to peripheral neuropathy, psychosis, and seizures through mitochondrial toxicity and oxidative stress. Chemotherapeutic agents presented perhaps the most profound neurotoxic effects, ranging from chronic peripheral neuropathy to persistent cognitive impairments, or "chemo brain," with mechanisms rooted in DNA damage, oxidative stress, and cytokine-driven neuroinflammation. This classification of neurotoxic outcomes not only provided a comprehensive overview of the clinical landscape but also served as a foundation for improving diagnostic, therapeutic, and monitoring strategies.

This research also highlighted the broader implications of neurotoxicity on patient care, illustrating how adverse neurological effects compromise treatment adherence, quality of life, and long-term health outcomes. For example, SAMS indirectly contributed to reduced physical activity and cognitive health, while chemotherapy-induced peripheral neuropathy profoundly limited patients' independence and functionality. Furthermore, the interplay between drug-induced neurotoxicity and polypharmacy posed significant challenges in clinical settings, with overlapping mechanisms intensifying adverse effects and complicating diagnosis. These findings underscored the necessity for interdisciplinary approaches to pharmacotherapy, integrating neurological assessments with routine clinical practice to minimize preventable neurotoxicity.

While the study successfully addressed its objectives, several limitations should be acknowledged. The reliance on existing literature presented challenges in reconciling conflicting data across studies, particularly where evidence on neurotoxic effects remains fragmented, as in the cases of PPIs and antihistamines. Furthermore, the absence of primary data collection constrained the exploration of causal relationships between drug use and neurotoxicity, especially in contexts involving multifactorial risk factors like age, genetic predispositions, and comorbidities. Additionally, indirect neurotoxic pathways, such as those mediated by the gut-brain axis, require further validation through experimental and clinical research to confirm their role in cognitive and neurological impairments. Despite these limitations, the work provides a valuable synthesis of current knowledge, offering a cohesive framework for understanding the complexities of medication-induced neurotoxicity.

Placing this research within the broader context of existing studies, it aligns with prior findings on the neurotoxic effects of chemotherapy, SSRIs, and fluoroquinolones while contributing novel insights into lesser-studied drug classes like PPIs and gastrointestinal agents. By integrating mechanistic, clinical, and patient-specific dimensions, this work bridges gaps in the literature,

presenting a unified perspective on the interplay between pharmacodynamics, neurotoxicity, and patient outcomes. The practical relevance of these findings lies in their potential to inform prescribing practices, enhance patient monitoring, and guide the development of safer drug formulations.

Looking forward, this study highlights several avenues for future research. Longitudinal studies are needed to assess the long-term neurological consequences of chronic drug use across diverse patient populations, capturing subtle or delayed effects that often escape detection in short-term investigations. Targeted research should also delve deeper into underexplored drug classes and emerging mechanisms, such as the role of the gut-brain axis or mitochondrial proteomics in mediating neurotoxic effects. Interdisciplinary collaborations integrating clinical medicine, molecular biology, and genetics hold promise for elucidating the multifactorial nature of neurotoxicity and advancing personalized therapeutic strategies. Additionally, the development of neuroprotective adjuncts, such as antioxidants, anti-inflammatory agents, or BBB stabilizers, represents a critical step toward minimizing the neurological burden of pharmacotherapy. Translational research efforts should prioritize bridging laboratory findings with clinical applications to enhance treatment efficacy and safety.

In reflecting on this research journey, the study underscores the profound complexity of pharmacology and its interplay with the nervous system. The motivation to pursue this topic stemmed from a commitment to advancing patient safety, addressing gaps in the understanding of drug-induced harm, and fostering a culture of informed, individualized care. Through this exploration, a deeper appreciation has emerged for the nuanced trade-offs between therapeutic efficacy and potential risks, as well as the ethical responsibility to minimize unnecessary harm in medical practice. By advocating for evidence-based approaches and patient-centered strategies, this work aspires to contribute meaningfully to the ongoing evolution of pharmacotherapy, ensuring that its benefits are realized without compromising neurological health.

13. Bibliography

Al-Hasani, N. (n.d.). Drugs affecting the cardiovascular system. University of Baghdad, College of Dentistry, lecture. https://codental.uobaghdad.edu.iq/wp-content/uploads/sites/14/2019/09/Pharmacology-LEC-6-Dr.-Al-Hasani.pdf

Aldubayan, M.A., Alsharidah, A.S., Alenez, S.K., & Alhowail, A.H. (2024). Galantamine mitigates neurotoxicity caused by doxorubicin via reduced neuroinflammation, oxidative stress, and apoptosis in a rat model. European Review for Medical and Pharmacological Sciences, 28(2), 805–813. https://www.europeanreview.org/wp/wp-content/uploads/805-813.pdf

Anwar, A.I., et al. (2024). Fluoroquinolones: Neurological complications and side effects in clinical practice. Cureus, 16(2), e54565. https://doi.org/10.7759/cureus.54565

Bashir, M.I., Aziz, N.H.K.A., & Noor, D.A.M. (2021). An updated review on some neurotoxic pharmacological agents along with their neurotoxic mechanisms. Medico-Legal Update, 21(2), 821–825. https://pdfs.semanticscholar.org/e207/722a544d16c77f929ed54699f2acded880a1.pdf

Bruhns, R.P., et al. (2018). Survival as a function of nonsteroidal anti-inflammatory drug use in patients with glioblastoma. Cureus, 10(9), 1–8. https://doi.org/10.7759/cureus.3277

Buduhan, V., et al. (2018). Symptom management guidelines: Chemotherapy–induced peripheral neuropathy (CIPN). http://www.bccancer.bc.ca/nursing-site/Documents/15.%20Peripheral%20Neuropathy.pdf

Calvo-Rodríguez, M., Núñez, L., & Villalobos, C. (2015). Non-steroidal anti-inflammatory drugs (NSAIDs) and neuroprotection in the elderly. Neural Regeneration Research, 10(9), 1371–1372. https://doi.org/10.4103/1673-5374.165219

Cheong, M., et al. (2020). Prevalence and risk factors of baclofen neurotoxicity in patients with severely impaired renal function. Nefrologia, 40(5), 543–551. https://doi.org/10.1016/j.nefro.2020.03.004

Duma, S.R., & Fung, V.S. (2019). Drug-induced movement disorders. Australian Prescriber, 42(2), 56–61. https://doi.org/10.18773/austprescr.2019.014

El Majzoub, I., et al. (2019). Management of altered mental status and delirium in cancer patients. Annals of Palliative Medicine, 8(5), 728–739. https://doi.org/10.21037/apm.2019.09.14

Gibler, A. (2015). Literature scan: Fluoroquinolone antibiotics. Drug Use Research & Management Program, Oregon State University, 1–7. http://www.orpdl.org/durm/meetings/meetingdocs/2015_05_28/finals/FluoroquinolonesLiteratureScanFINAL.pdf

Hansen, N., Finzel, M., & Block, F. (2010). Antiepileptic drug-induced encephalopathy. Fortschritte der Neurologie Psychiatrie, 1–78. https://doi.org/10.1055/s-0029-1245632

Hnepa, Y.Y., et al. (2021). Short- and long-term effects of NSAIDs on the gastrointestinal mucosa: Complex analysis of benefits and complications prevention. Wiadomości Lekarskie, 74(4), 1011–1018. https://doi.org/10.36740/WLek202104138

Iqubal, A., et al. (2018). Clinical updates on drug-induced cardiotoxicity. International Journal of Pharmaceutical Sciences and Research, 9(1), 16–26. https://doi.org/10.13040/IJPSR.0975-8232.9(1).16-26

Izumi, Y., et al. (2023). SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids. Translational Psychiatry, 13(1), 1–9. https://doi.org/10.1038/s41398-023-02343-3

Jing, Y., Lv, H.Y., & Feng, S.W. (2016). The trend of chemotherapy-induced peripheral neurotoxicity in ovarian cancer survivors and its impacts on daily life during and one year after treatment. European Journal of Gynaecological Oncology, 37(5), 695–699. https://doi.org/10.12892/ejgo3267.2016

Jóźwik-Plebanek, K., et al. (2020). Blood pressure profile, sympathetic nervous system activity, and subclinical target organ damage in patients with polycythemia vera. Polish Archives of Internal Medicine, 130(7–8), 607–614. https://doi.org/10.20452/pamw.15473

Kamath, A. (2013). Fluoroquinolone induced neurotoxicity: A review. Journal of Advanced Pharmacy Education & Research, 3(1), 16–19. https://japer.in/storage/models/article/XGMyxG5Zs13aIXBUyjaqefsw3D4LgVS5U1762EbiS22kAf

KYpDfmJVrOT7b5/fluoroquinolone-induced-neurotoxicity-a-review.pdf

Kawade, D.P., & Hedaoo, M.Y. (2019). Applications of nasal NSAIDs in Alzheimer's disease. World Journal of Pharmaceutical Research, 8(7), 448–473. https://doi.org/10.20959/wjpr20197-14966

Khilnani, G., Khilnani, A.K., & Thaddanee, R. (2020). Learning pharmacology by metaphors: A tale of antihistamines. National Journal of Physiology, Pharmacy and Pharmacology, 10(8), 693–700. https://doi.org/10.5455/njppp.2020.10.04095202002052020

Kozłowski, P., et al. (2015). Levetiracetam – epilepsy treatment, pharmacokinetics, mechanism of action, interaction and toxicity. Journal of Education, Health and Sport, 5(4), 143–150. https://doi.org/10.5281/zenodo.16694

Kufiah, H.Z., et al. (2019). Neurological effect of drugs: An overview. EC Pharmacology and Toxicology, 7(3), 161–170. https://ecronicon.net/assets/ecpt/pdf/ECPT-07-00265.pdf

Lertvipapath, P., & Warunyuwong, W. (2020). Beta-blocker and its neuropsychiatric effects. Thai Journal of Pharmaceutical Sciences, 44(2), 117–123. https://www.thaiscience.info/Journals/Article/TJPS/10996288.pdf

Liu, Z., et al. (2018). A study on the relationship between chemotherapy-induced cognitive impairment and age in patients with breast cancer. JBUON, 23(6), 1601–1605. https://jbuon.com/archive/23-6-1601.pdf

Myers, J.S., Pierce, J., & Pazdernik, T. (2008). Neurotoxicology of chemotherapy in relation to cytokine release, the blood-brain barrier, and cognitive impairment. Oncology Nursing Forum, 35(6), 916–920. https://doi.org/10.1188/08.ONF.916-920

Popescu, F.D. (2008). H1 antihistamines and driving. Journal of Medicine and Life, 1(3), 262–268. https://medandlife.org/wp-content/uploads/JMedLife-1-262.pdf

Pryadko, A.O., et al. (2015). Microscopic features of buccal epithelium of the Indian students studying at Belgorod State National Research University. Scientific Result: Medicine and Pharmacy Series, 1(4), 45–49. https://doi.org/10.18413/2313-8955-2015-1-4-45-49

Remesh, A. (2012). Toxicities of anticancer drugs and its management. International Journal of Basic & Clinical Pharmacology, 1(1), 2–12. https://doi.org/10.5455/2319-2003.ijbcp000812

Schatz, S.N., & Weber, R.J. (2015). Adverse drug reactions. Pharmacotherapy Self-Assessment Program (PSAP), 5–26. https://www.accp.com/docs/bookstore/psap/2015B2.SampleChapter.pdf

Schultz, L., et al. (2015). Evaluation of drug-induced neurotoxicity based on metabolomics, proteomics and electrical activity measurements in complementary CNS in vitro models. Toxicology in Vitro, 30, 138–165. https://doi.org/10.1016/j.tiv.2015.05.016

Shuper, A., et al. (2002). Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. IMAJ, 4(Nov), 1050–1053. https://www.ima.org.il/filesupload/IMAJ/0/57/28575.pdf

Smyth, D., et al. (2023). Toxic neuropathies: A practical approach. Practical Neurology, 23(2), 120–130. https://doi.org/10.1136/practneurol-2022-003444

Spencer, P.S., & Lein, P.J. (2024). Neurotoxicity. In Encyclopedia of Toxicology (4th ed., pp. 727–740). https://doi.org/10.1016/b978-0-12-824315-2.00548-0

Staat, K., & Segatore, M. (2005). The phenomenon of chemo brain. Clinical Journal of Oncology Nursing, 9(6), 713–721. https://doi.org/10.1188/05.CJON.713-721

Tournadre, A. (2020). Statins, myalgia, and rhabdomyolysis. Joint Bone Spine, 87(1), 37–42. https://doi.org/10.1016/j.jbspin.2019.01.018

Tsai, Y.H., & Lein, P.J. (2021). Mechanisms of organophosphate neurotoxicity. Current Opinion in Toxicology, 26, 49–60. https://doi.org/10.1016/j.cotox.2021.04.002

U.T. M.D. Anderson Cancer Center. (2024). Opioid-induced neurotoxicity. https://www.mdanderson.org/content/dam/mdanderson/documents/education-training/project-echo/Palliative_CEA_Opioid-Induced%20Neurotoxicity.pdf

Urban, M., Navrátil, T., & Pelclová, D. (2013). Trends in CNS affecting drugs in the calls to the Toxicological Information Center from 1997 to 2012. Neuroendocrinology Letters, 34(Suppl. 2), 25–

30. https://www.nel.edu/userfiles/articlesnew/NEL341013A04.pdf

von der Weid, N. (2001). Late effects in long-term survivors of ALL in childhood: Experiences from the SPOG late effects study. Swiss Medical Weekly, 131, 180–187. https://serval.unil.ch/resource/serval:BIB_265FC3B6D64A.P001/REF.pdf

Was, H., et al. (2022). Mechanisms of chemotherapy-induced neurotoxicity. Frontiers in Pharmacology, 13, 1–31. https://doi.org/10.3389/fphar.2022.750507

Weimer, L.H. (2016). Toxic neuropathy. Columbia University Medical Center. https://www.hnf-cure.org/wp-content/uploads/2017/03/HNF-Neurotoxic-List.pdf

Zhang, W., Matsukane, R., Egashira, N., Tsuchiya, Y., Fu, R., Yamamoto, S., Hirota, T., & Ieiri, I. (2022). Neuroprotective effects of ibudilast against tacrolimus-induced neurotoxicity. Toxicology and Applied Pharmacology, 449, 116112. https://doi.org/10.1016/j.taap.2022.116112

12. Pledge

Vilniaus universiteto studento, teikiančio baigiamąjį darbą, GARANTIJA

Vardas ir pavardė: Abhishek Krishna Sharma
Padalinys: Medicinos Fakultetas
Studijų programa: Medicina
Darbo pavadinimas: Už etiketės ribų: literatūros apžvalga apie kasdien vartojamų vaistų neurotoksinį poveikį.
Darbo tipas: Magistro darbas

Garantuoju, kad mano baigiamasis darbas yra parengtas sąžiningai ir savarankiškai, kitų asmenų indėlio į parengtą darbą nėra. Jokio neteisėto atlygio už šį darbą niekam nesu mokėjęs. Šiame darbe tiesiogiai ar netiesiogiai panaudotos kitų šaltinių citatos pažymėtos literatūros nuorodose.

PLEDGE of Vilnius University student submitting a thesis

Given name and surname: Abhishek Krishna Sharma
Faculty: Faculty of Medicine
Study programme: Medicine
Thesis topic: Beyond the Label: A Literature Review on the Neurotoxic Effects of Everyday Medications.
Thesis type: Master's Thesis

I pledge that my thesis has been prepared in good faith and independently and that there has been no contribution by other individuals to this thesis. I have not made any illegal payments related to this thesis. Quotes from other sources used in this thesis, directly or indirectly, are indicated in the list of references

Aš, Abhishek Krishna Sharma, patvirtinu (pažymėti)
I, Abhishek Krishna Sharma, *confirm (check)*

Patvirtinu, kad baigiamasis darbas yra įkeltas į Vilniaus universiteto studijų informacinę sistemą.
I declare that this thesis has been uploaded to the Vilnius University Study Information System

Abhishek Krishna Sharma	A Sharma	2025.05.10
(vardas ir pavardė / name, surname)	(parašas / signature)	(data / date)